var title_f19_29_19920="TB pleural effusion CT";
var content_f19_29_19920=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F63772&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F63772&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Tuberculous pleural effusion",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 292px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    CT scan showing a parenchymal focus of tuberculosis close to the pleura and an ipsilateral pleural effusion.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_29_19920=[""].join("\n");
var outline_f19_29_19920=null;
var title_f19_29_19921="Proboscoid hernia";
var content_f19_29_19921=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F63270&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F63270&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Proboscoid hernia warranting early repair",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 367px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Mary L Brandt, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_29_19921=[""].join("\n");
var outline_f19_29_19921=null;
var title_f19_29_19922="Port placement left colectomy";
var content_f19_29_19922=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F70436&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F70436&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 477px\">",
"   <div class=\"ttl\">",
"    Port placement left colectomy*",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 457px; height: 587px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    An open technique is used to enter the peritoneal cavity and place a 5 to 12 mm Hasson trocar at the umbilicus. The laparoscope is introduced through this port. Two ports are placed under direct vision in the lower abdomen and one or more 5 mm ports placed in the upper midline.",
"    <br>",
"     The surgeon and the assistant stand on the patient's right side. Either the suprapubic port or the right lower quadrant port can be used to introduce the surgical stapler for transection of the colon. The upper midline port is useful for mobilizing the splenic flexure. The resected colon can be removed through a mini-laparotomy at the umbilicus or through a small Pfannenstiel incision.",
"     <div class=\"footnotes\">",
"      * Port placement and technique may vary amongst laparoscopic surgeons.",
"     </div>",
"     <div class=\"reference\">",
"     </div>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_29_19922=[""].join("\n");
var outline_f19_29_19922=null;
var title_f19_29_19923="Development of the atrial septum primum";
var content_f19_29_19923=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F86165&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F86165&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 561px\">",
"   <div class=\"ttl\">",
"    Development of the atrial septum primum",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 541px; height: 486px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_29_19923=[""].join("\n");
var outline_f19_29_19923=null;
var title_f19_29_19924="Calcium polystyrene sulfonate: Patient drug information";
var content_f19_29_19924=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Calcium polystyrene sulfonate: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/8/24708?source=see_link\">",
"     see \"Calcium polystyrene sulfonate: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F9646930\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Resonium Calcium&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10023551\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10023553\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691893",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat high potassium levels.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10023552\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705254",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to calcium polystyrene sulfonate or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705287",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high calcium or bowel block.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10023557\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696833",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take antacids within 2 hours of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10023558\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697978",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hard stools (constipation). Drinking more liquids, working out, or adding fiber to your diet may help. Talk with your doctor about a stool softener or laxative.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698984",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not hungry.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698217",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of low potassium levels like muscle pain or weakness, muscle cramps, or a heartbeat that does not feel normal.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10023560\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699072",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of low potassium.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699014",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very hard stools (constipation).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10023555\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705490",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Oral:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695426",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Mix powder with liquid and drink. Do not mix with orange juice.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705519",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Rectal:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696173",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use enema rectally.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10023556\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696549",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Many times this drug is used on an as needed basis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10023561\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10023562\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699681",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Read the package insert for more details.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11522 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-210.101.131.232-F6895ED81D-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_29_19924=[""].join("\n");
var outline_f19_29_19924=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9646930\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023551\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023553\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023552\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023557\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023558\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023560\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023555\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023556\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023561\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023562\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?24/8/24708?source=related_link\">",
"      Calcium polystyrene sulfonate: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_29_19925="Valganciclovir: Patient drug information";
var content_f19_29_19925=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Valganciclovir: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/37/5718?source=see_link\">",
"     see \"Valganciclovir: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?21/18/21798?source=see_link\">",
"     see \"Valganciclovir: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F232941\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Valcyte&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F232942\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Valcyte&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10017336\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700847",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may have anemia, low platelet counts, or low white blood cell counts. Change in dose or even stopping the drug may be needed if you have any of these side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3652592",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use during pregnancy may cause birth defects. Women need to use a helpful kind of birth control while taking this drug and for 1 month after stopping this drug. Men must use a latex condom to protect their partner from becoming pregnant while taking this drug and for 3 months after stopping this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700703",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may cause you to not be able to get pregnant. Talk with the doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3484608",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may add to your chance of getting some types of cancer. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10017338\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691682",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat a viral infection of the eyes.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10017337\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700988",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take ganciclovir while taking this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703114",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to valganciclovir, acyclovir, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10017342\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698463",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have an eye exam every year.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697712",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       To protect from diseases caused by having sex, use a latex condom.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696712",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is best not to breast-feed.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10017343\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697876",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Anemia, low white blood cell count, and low platelet count.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698134",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       High blood pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698081",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Fever.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697983",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Cough.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698162",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to sleep.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10017345\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698988",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Numbness or tingling in your hands or feet.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699099",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Twitching.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699104",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to pass urine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10017340\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695907",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take this drug with food.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694218",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       There is a liquid if you cannot swallow pills.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694818",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Drink lots of noncaffeine liquids unless told to drink less liquid by your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10017341\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696562",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it, with a meal.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10017346\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705564",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Tablet:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2696421",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Liquid:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2907719",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store liquid (solution) in a refrigerator. Throw away any part not used after 7 weeks.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10017347\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11135 Version 31.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-41.78.124.10-9FDBE1AB85-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_29_19925=[""].join("\n");
var outline_f19_29_19925=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F232941\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F232942\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017336\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017338\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017337\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017342\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017343\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017345\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017340\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017341\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017346\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017347\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?5/37/5718?source=related_link\">",
"      Valganciclovir: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?21/18/21798?source=related_link\">",
"      Valganciclovir: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_29_19926="Cyanide antidote kit: Pediatric drug information";
var content_f19_29_19926=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Cyanide antidote kit: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?14/16/14598?source=see_link\">",
"    see \"Cyanide antidote kit: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?9/55/10099?source=see_link\">",
"    see \"Cyanide antidote kit: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F155081\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Cyanide Antidote Package",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1057461\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antidote, Cyanide",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1057455\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?14/16/14598?source=see_link\">",
"      see \"Cyanide antidote kit: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Cyanide poisoning:",
"     </b>",
"     Infants, Children, Adolescents, and Adults:",
"     <b>",
"      Note:",
"     </b>",
"     Administer in sequential order. Monitor the patient for 24-48 hours.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Step 1:",
"     <b>",
"      Amyl nitrite:",
"     </b>",
"     Inhalation: 0.3 mL ampul crushed into a gauze pad and placed in front of the patient&rsquo;s mouth (or endotracheal tube if patient is intubated) to inhale over 15-30 seconds; repeat every minute  until sodium nitrite can be administered.",
"     <b>",
"      Note:",
"     </b>",
"     Must separate administrations by at least 30 seconds to allow for adequate oxygenation; each ampul will last for ~3 minutes.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Step 2: When the I.V. site is established, discontinue the use of inhaled amyl nitrite and begin sodium nitrite based on the following dosage recommendations; the preparation and administration of sodium nitrite should not be delayed in preference to administering amyl nitrite:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Sodium nitrite:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Manufacturer's labeling:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Infants, Children, and Adolescents: I.V.: Initial dose: 3% solution: 0.2 mL/kg; maximum dose: 10 mL (300 mg); if repeat dosing is necessary due to symptom return, use 50% of the original dose.",
"     <b>",
"      Note:",
"     </b>",
"     Presented dose equates to 6 mg/kg of sodium nitrite",
"     <b>",
"      or",
"     </b>",
"     6-8 mL/",
"     <b>",
"      m",
"      <sup>",
"       2",
"      </sup>",
"     </b>",
"     of the 3% solution.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Adults: I.V.: Initial dose: 3% solution: 10 mL (300 mg); if repeat dosing is necessary due to symptom return, use 50% of the original dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Alternate dosing: Hemoglobin dependent dosing: For patients who are unable to tolerate significant methemoglobinemia (eg, patients with comorbidities that compromise oxygen delivery, such as heart disease, lung disease, etc), dosing may be based on hemoglobin levels (when rapid bedside testing is available) to prevent fatal methemoglobinemia; see table (Berlin, 1970):",
"    </p>",
"    <table border=\"1\" frame=\"border\" rules=\"all\">",
"     <col align=\"center\" width=\"125\">",
"     </col>",
"     <col align=\"center\" width=\"200\">",
"     </col>",
"     <thead valign=\"middle\">",
"      <tr>",
"       <th align=\"center\" colspan=\"2\">",
"        <p style=\"text-indent:0em;\">",
"         Dosing Based on Hgb Level",
"        </p>",
"       </th>",
"      </tr>",
"      <tr>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Hemoglobin Level (g/dL)",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Dose of 3% Sodium Nitrite Solution",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         (Maximum dose: 10 mL)",
"        </p>",
"       </th>",
"      </tr>",
"     </thead>",
"     <tbody valign=\"top\">",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         7",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         0.19 mL/kg",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         8",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         0.22 mL/kg",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         9",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         0.25 mL/kg",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         10",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         0.27 mL/kg",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         11",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         0.3 mL/kg",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         12",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         0.33 mL/kg",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         13",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         0.36 mL/kg",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         14",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         0.39 mL/kg",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Step 3:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Sodium thiosulfate: Note:",
"     </b>",
"     Sodium thiosulfate is available as a 10% and 25% concentration and as part of various antidote kits or as a single product. Some dosing is concentration-dependent; verify product strength prior to dose calculation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Infants, Children, and Adolescents:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Manufacturer&rsquo;s labeling: I.V.: 7",
"     <b>",
"      g",
"     </b>",
"     /m",
"     <sup>",
"      2",
"     </sup>",
"     ; maximum dose: 12.5",
"     <b>",
"      g",
"     </b>",
"     ; if repeat dosing is necessary due to symptom return, use 50% of the original dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Alternate dosing: Volume-based: I.V.: Initial: 25% solution: 1 mL/kg; maximum dose: 50 mL (12.5",
"     <b>",
"      g",
"     </b>",
"     ); if repeat dosing necessary due to symptom return, use 50% of the original dose.",
"     <b>",
"      Note:",
"     </b>",
"     Presented dose equates to 250 mg/kg  of sodium thiosulfate or 28-40 mL/",
"     <b>",
"      m",
"      <sup>",
"       2",
"      </sup>",
"     </b>",
"     of the 25% solution. Dosing from Nithiodote&trade; manufacturer&rsquo;s labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: I.V.: Initial: 25% solution: 50 mL (12.5",
"     <b>",
"      g",
"     </b>",
"     ); if repeat dosing is necessary due to symptom return, use 50% of the original dose.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F155073\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Kit [each kit contains] (Cyanide Antidote Package):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Injection, solution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Sodium nitrite 300 mg/10 mL (2)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Sodium thiosulfate 12.5 g/50 mL (2)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Inhalant: Amyl nitrite 0.3 mL (12)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     [kit also includes disposable syringes, stomach tube, tourniquet, and instructions]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F155063\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1057466\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Inhalation:",
"     <b>",
"      Amyl nitrite:",
"     </b>",
"     Crush ampul into a gauze pad and place in front of patient&rsquo;s mouth (or endotracheal tube if intubated) and allow patient to inhale for 15-30 seconds; repeat every minute until sodium nitrite can be administered. One ampul lasts for ~3 minutes.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Parenteral: I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Sodium nitrite:",
"     </b>",
"     Administer undiluted at a rate of 2.5-5 mL/minute",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Sodium thiosulfate:",
"     </b>",
"     Administer undiluted over at least 10-20 minutes; rapid administration may cause hypotension. Decrease rate of infusion in the event of significant hypotension, nausea, or vomiting.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F3149032\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Y-site administration: Incompatible:",
"     </b>",
"     Hydroxocobalamin.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1057458\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F)",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1057465\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of cyanide poisoning [FDA approved in pediatric patients (age not specified) and adults]",
"    </p>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F155094\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Amyl nitrite:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Cerebral ischemia, facial flushing, hypotension, orthostatic hypotension, pallor, shock, syncope, tachycardia, vasodilation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Dizziness, headache, intracranial pressure increased, restlessness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Dermatitis, irritation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Fecal incontinence, nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Urinary incontinence",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Hemolytic anemia, methemoglobinemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Intraocular pressure increased, irritation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Diaphoresis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Sodium nitrite:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Arrhythmias, cyanosis, flushing, hypotension, palpitations, syncope, tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Anxiety, coma, confusion, dizziness, fatigue, headache, lightheadedness, seizure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Acidosis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Methemoglobinemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Injection site tingling",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Numbness, paresthesia, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Blurred vision",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Dyspnea, tachypnea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Diaphoresis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Sodium thiosulfate:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Hypotension",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Disorientation, headache",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea, salty taste, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Bleeding time prolonged",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Warmth",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1057468\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to amyl nitrite, sodium nitrite, sodium thiosulfate, or any component",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1057454\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use amyl nitrite with caution in patients with glaucoma, recent head trauma, or cerebral hemorrhage; may increase intraocular and intracranial pressure. Use amyl nitrite with caution in patients with coronary artery disease and patients with hypotension. Transient episodes of dizziness, weakness, syncope, and cerebral ischemia secondary to postural hypotension may occur. Use with caution in patients with G6PD deficiency; increased risk for hemolytic crisis following sodium nitrite administration; monitor for an acute drop in hematocrit. Concurrent use of antihypertensives, diuretics, phosphodiesterase-5 enzyme (PDE5) inhibitors, and medications known to cause methemoglobinemia should be done with caution.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1057453\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Amyl nitrite and sodium nitrite may cause methemoglobin formation and severe hypotension resulting in diminished oxygen-carrying capacity; serious adverse effects may occur at doses less than twice the recommended therapeutic dose. Monitor for adequate perfusion and oxygenation; ensure patient is euvolemic. Use with caution in patients with pre-existing diminished oxygen or cardiovascular reserve [eg, smoke inhalation victims, anemia (dosage reduction in proportion to oxygen carrying capacity is recommended), substantial blood loss, and cardiac or respiratory compromise], in patients at greater risk for developing methemoglobinemia (eg, neonates and infants &lt;6 months or patients with congenital methemoglobin reductase deficiency) and in patients who may be susceptible to injury from vasodilation; the use of hydroxocobalamin is recommended in these patients. Amyl nitrite may cause harm to the fetus if administered to a pregnant woman; may significantly decrease systemic blood pressure and blood flow.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Due to the risk of serious adverse effects, use with caution in patients where the diagnosis of cyanide poisoning is uncertain. However, if clinical suspicion of cyanide poisoning is high, treatment should not be delayed. Treatment of cyanide poisoning should include decontamination and supportive therapy.  Collection of pretreatment blood cyanide concentrations does not preclude administration and should not delay administration in the emergency management of highly suspected or confirmed cyanide toxicity. Pretreatment levels may be useful as postinfusion levels may be inaccurate. Monitor patients for return of symptoms for 24-48 hours; repeat treatment should be administered if symptoms return. Consider consultation with a poison control center at 1-800-222-1222.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Fire victims may present with both cyanide and carbon monoxide poisoning. Carbon monoxide  poisoning leads to carboxyhemoglobinemia which decreases the oxygen-carrying capacity; use of amyl and/or sodium nitrite which induces methemoglobinemia may worsen oxygen-carrying capacity. In this scenario, sodium thiosulfate may be used alone to promote the clearance of cyanide. Due to the slow onset of actions of sodium thiosulfate, may consider using hydroxocobalamin  alone or in combination with sodium thiosulfate (Howland, 2011). The presence of sulfite hypersensitivity should not preclude the use of this medication.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13300062\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F155069\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypotensive Agents: May enhance the adverse/toxic effect of other Hypotensive Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphodiesterase 5 Inhibitors: May enhance the vasodilatory effect of Amyl Nitrite.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prilocaine: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Prilocaine. Combinations of these agents may increase the likelihood of significant methemoglobinemia.  Management: Monitor patients for signs of methemoglobinemia (e.g., hypoxia, cyanosis) when prilocaine is used in combination with other agents associated with development of methemoglobinemia.  Avoid lidocaine/prilocaine in infants receiving such agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F14287358\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1057460\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Monitor for at least 24-48 hours after administration; blood pressure and heart rate during and after infusion; hemoglobin/hematocrit; co-oximetry; serum lactate levels; venous-arterial PO",
"     <sub>",
"      2",
"     </sub>",
"     gradient; serum methemoglobin and oxyhemoglobin. Pretreatment cyanide levels may be useful diagnostically.",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F1057464\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Symptoms associated with blood cyanide levels:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Flushing and tachycardia: 0.5-1 mcg/mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Obtundation: 1-2.5 mcg/mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Coma and respiratory depression: &gt;2.5 mcg/mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Death: &gt;3 mcg/mL",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1057452\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nitrites: Promote the formation of methemoglobin which competes with cytochrome oxidase for the cyanide ion. Cyanide combines with methemoglobin to form cyanomethemoglobin, thereby freeing the cytochrome oxidase and allowing aerobic metabolism to continue.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium thiosulfate: Serves as a sulfur donor in rhodanese-catalyzed formation of thiocyanate (much less toxic than cyanide).",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F15589798\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Sodium nitrite:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Onset: Peak effect: Methemoglobinemia: 30-60 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Duration: Methemoglobinemia: ~55 minutes",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F15589799\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Amyl nitrite:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Absorption: Inhalation: Readily absorbed through respiratory tract",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Metabolism: In the liver to form inorganic nitrates (less potent)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Half-life:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Amyl nitrite: &lt;1 hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Methemoglobin: 1 hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Elimination: Renal; ~33%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Sodium nitrite:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Metabolism: To ammonia and other metabolites",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Elimination: Urine (~40% as unchanged drug)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Sodium thiosulfate:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Half-life elimination:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Thiosulfate: ~3 hours (Howland, 2011)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Thiocyanate: ~3 hours; renal impairment: &le;9 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Elimination: Urine (~20% to 50% as unchanged drug)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Agency for Toxic Substances and Disease Registry (ATSDR), &ldquo;Medical Management Guidelines for Hydrogen Cyanide (HCN).&rdquo; Available at",
"      <a href=\"file://www.atsdr.cdc.gov/MHMI/mmg8.pdf\" target=\"_blank\">",
"       file://www.atsdr.cdc.gov/MHMI/mmg8.pdf",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Berlin CM Jr, \"The Treatment of Cyanide Poisoning in Children,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1970, 46(5):793-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/29/19926/abstract-text/4320419/pubmed\" id=\"4320419\" target=\"_blank\">",
"        4320419",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Geller RJ, Barthold C, Saiers JA, et al, \"Pediatric Cyanide Poisoning: Causes, Manifestations, Management, and Unmet Needs,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2006, 118(5):2146-58.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/29/19926/abstract-text/17079589/pubmed\" id=\"17079589\" target=\"_blank\">",
"        17079589",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gracia R and Shepherd G, &ldquo;Cyanide Poisoning and Its Treatment,&rdquo;",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 2004, 24(10):1358-65.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/29/19926/abstract-text/15628833/pubmed\" id=\"15628833\" target=\"_blank\">",
"        15628833",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hall AH, Dart R, and Bogdan G, &ldquo;Sodium Thiosulfate or Hydroxocobalamin for the Empiric Treatment of Cyanide Poisoning?&rdquo;",
"      <i>",
"       Ann Emerg Med",
"      </i>",
"      , 2007, 49(6):806-13.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/29/19926/abstract-text/17098327/pubmed\" id=\"17098327\" target=\"_blank\">",
"        17098327",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Howland MA, &ldquo;Antidotes in Depth: Sodium and Amyl Nitrite,&rdquo;",
"      <i>",
"       Goldfrank's Toxicologic Emergencies",
"      </i>",
"      , 9th ed, Nelson LS, Hoffman RS, Lewin NA, et al, eds, New York, NY: McGraw-Hill Companies, Inc, 2011, 1519-22.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Howland MA, &ldquo;Antidotes in Depth: Sodium Thiosulfate,&rdquo;",
"      <i>",
"       Goldfrank's Toxicologic Emergencies",
"      </i>",
"      , 9th ed, Nelson LS, Hoffman RS, Lewin NA, et al, eds, New York, NY: McGraw-Hill Companies, Inc, 2011.",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12709 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-61.55.141.10-1AFF26D322-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_29_19926=[""].join("\n");
var outline_f19_29_19926=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155081\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057461\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057455\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155073\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155063\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057466\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3149032\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057458\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057465\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155094\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057468\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057454\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057453\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13300062\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155069\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14287358\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057460\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057464\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057452\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15589798\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15589799\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12709\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12709|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?14/16/14598?source=related_link\">",
"      Cyanide antidote kit: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?9/55/10099?source=related_link\">",
"      Cyanide antidote kit: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_29_19927="Pseudocyesis";
var content_f19_29_19927=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pseudocyesis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/29/19927/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/29/19927/contributors\">",
"     Orit Avni-Barron, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/29/19927/contributors\">",
"     Renu Gupta, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/29/19927/contributors\">",
"     Laura J Miller, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/29/19927/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/29/19927/contributors\">",
"     Joel Dimsdale, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/29/19927/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/29/19927/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?19/29/19927/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 12, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H13130904\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pseudocyesis (false pregnancy) has captured the imagination of both clinicians and nonclinicians for centuries, and has been featured in multiple books, movies and television shows. In this rare clinical syndrome, a non-pregnant, non-psychotic woman believes she is pregnant and exhibits signs and symptoms of pregnancy.&nbsp;The Diagnostic and Statistical Manual of Mental Disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?19/29/19927/abstract/1\">",
"     1",
"    </a>",
"    ] includes pseudocyesis under Somatoform Disorder Not Otherwise Specified (NOS).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H977486891\">",
"    <span class=\"h1\">",
"     PREVALENCE AND EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pseudocyesis affects all ethnic, racial, and socioeconomic groups [",
"    <a class=\"abstract\" href=\"UTD.htm?19/29/19927/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. It is most common in women aged 20 to 39 years, but has been described in premenarchal and postmenopausal women. In one historic series of 444 cases dating back to the 17",
"    <sup>",
"     th",
"    </sup>",
"    and 18",
"    <sup>",
"     th",
"    </sup>",
"    centuries, most patients were married and at least 40 percent had given birth previously [",
"    <a class=\"abstract\" href=\"UTD.htm?19/29/19927/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although accurate prevalence figures are not available, pseudocyesis has been posited to be more prevalent in cultures where childbearing is the central role of women, and fertility (or cultural pressure for giving birth to a child of&nbsp;a specific sex) is a prerequisite for marriage or for a stable relationship. With trends towards smaller family size in developed countries, the incidence of pseudocyesis tends to decrease [",
"    <a class=\"abstract\" href=\"UTD.htm?19/29/19927/abstract/4\">",
"     4",
"    </a>",
"    ], although immigrants may remain at risk [",
"    <a class=\"abstract\" href=\"UTD.htm?19/29/19927/abstract/5-8\">",
"     5-8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13130911\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical presentation of pseudocyesis has both psychological and physiological aspects. Affected women have a belief that they are pregnant and also have one or more of the following signs or symptoms:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Abdominal enlargement",
"     </li>",
"     <li>",
"      Menstrual irregularities",
"     </li>",
"     <li>",
"      Sensation of fetal movement",
"     </li>",
"     <li>",
"      Gastrointestinal symptoms",
"     </li>",
"     <li>",
"      Breast changes",
"     </li>",
"     <li>",
"      Abdominal pain",
"     </li>",
"     <li>",
"      Urinary frequency",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The most common sign, abdominal enlargement, occurs without the typical effacement of the umbilicus observed in pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?19/29/19927/abstract/9\">",
"     9",
"    </a>",
"    ]. Abdominal protrusion can be due to gaseous distention, excess fat, pronounced lumbar lordosis, or",
"    <span class=\"nowrap\">",
"     fecal/urinary",
"    </span>",
"    retention, and often recedes with administration of general anesthesia [",
"    <a class=\"abstract\" href=\"UTD.htm?19/29/19927/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. Menstrual changes range from irregular cycles to amenorrhea. The subjective feeling of fetal movements tends to be atypical in pattern, intensity and duration, and may be due to contraction of the abdominal wall musculature or bowel peristalsis [",
"    <a class=\"abstract\" href=\"UTD.htm?19/29/19927/abstract/12\">",
"     12",
"    </a>",
"    ]. Nausea may present early, and may be the initial reason for the patient to suspect pregnancy; vomiting may also occur. There may be weight gain. Breast changes can include engorgement, tenderness, pigmentation, papillary enlargement, and galactorrhea or nipple discharge [",
"    <a class=\"abstract\" href=\"UTD.htm?19/29/19927/abstract/13\">",
"     13",
"    </a>",
"    ]. Pain can be severe, and usually occurs around the time that the woman regards as her expected date of delivery. Some women also experience increased urinary frequency.",
"   </p>",
"   <p>",
"    The initial presentation may be for routine prenatal care or for an acute pregnancy related problem (eg, pain, bleeding, labor, decreased fetal activity).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H977486860\">",
"    <span class=\"h2\">",
"     Laboratory",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endocrinologic changes can occur, but are inconsistent and no single neuroendocrine profile is common to all women with pseudocyesis. Prolactin, estrogen, progesterone, follicle stimulating hormone, and luteinizing hormone concentrations vary widely [",
"    <a class=\"abstract\" href=\"UTD.htm?19/29/19927/abstract/12,14\">",
"     12,14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13130918\">",
"    <span class=\"h1\">",
"     NATURAL HISTORY AND PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The natural history of pseudocyesis is not well described because of its low prevalence. Knowledge about pseudocyesis is derived from case reports and occasional case series.",
"   </p>",
"   <p>",
"    Symptoms generally last from a few weeks to nine months or longer, even years [",
"    <a class=\"abstract\" href=\"UTD.htm?19/29/19927/abstract/9\">",
"     9",
"    </a>",
"    ]. Recovery may be spontaneous, but is sometimes preceded by &ldquo;labor&rdquo; pain [",
"    <a class=\"abstract\" href=\"UTD.htm?19/29/19927/abstract/3\">",
"     3",
"    </a>",
"    ]. Women can experience a single, or multiple, episodes of pseudocyesis [",
"    <a class=\"abstract\" href=\"UTD.htm?19/29/19927/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the individual patient, prognosis is dependent, to a large extent, on resolution of the specific psychological",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    interpersonal factors that have been involved in the development of pseudocyesis in that patient. In some cases, pseudocyesis heralds the development of another psychiatric disorder, most often depression [",
"    <a class=\"abstract\" href=\"UTD.htm?19/29/19927/abstract/16,17\">",
"     16,17",
"    </a>",
"    ], but sometimes hypomania [",
"    <a class=\"abstract\" href=\"UTD.htm?19/29/19927/abstract/18\">",
"     18",
"    </a>",
"    ] or psychosis [",
"    <a class=\"abstract\" href=\"UTD.htm?19/29/19927/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. Some women with pseudocyesis eventually commit suicide [",
"    <a class=\"abstract\" href=\"UTD.htm?19/29/19927/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13130925\">",
"    <span class=\"h1\">",
"     PATHOGENESIS AND RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The development of pseudocyesis involves psychological and neuroendocrine mechanisms that affect each other in a reciprocal interplay between mind and body. There are three major hypotheses about the development of this disorder.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13130932\">",
"    <span class=\"h2\">",
"     Psychosomatic hypothesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;In this hypothesis, intense social pressure and anxiety alter the function of the hypothalamic-pituitary-ovarian axis, which results in signs and symptoms of pregnancy, such as amenorrhea [",
"    <a class=\"abstract\" href=\"UTD.htm?19/29/19927/abstract/22\">",
"     22",
"    </a>",
"    ]. Such pressure may include an overwhelming desire to be pregnant for personal reasons, cultural considerations, or both. In these cases, a belief in pregnancy is thought to serve as a defense against confrontation with a difficult reality [",
"    <a class=\"abstract\" href=\"UTD.htm?19/29/19927/abstract/23\">",
"     23",
"    </a>",
"    ], often related to a loss [",
"    <a class=\"abstract\" href=\"UTD.htm?19/29/19927/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Contributory psychological pressures include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Loss of fertility and reproductive capability (eg,&nbsp;sterilization surgery, hysterectomy, menopause, loss of a pregnancy or a child) [",
"      <a class=\"abstract\" href=\"UTD.htm?19/29/19927/abstract/25\">",
"       25",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Interpersonal pressures (eg, an attempt to maintain&nbsp;a relationship, parity with other women, loneliness, or family pressure) [",
"      <a class=\"abstract\" href=\"UTD.htm?19/29/19927/abstract/26\">",
"       26",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Fear of conceiving [",
"      <a class=\"abstract\" href=\"UTD.htm?19/29/19927/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Coping style characterized by somatization and denial [",
"      <a class=\"abstract\" href=\"UTD.htm?19/29/19927/abstract/27\">",
"       27",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Cognitive style characterized by using less information before coming to conclusions, to be more certain of conclusions, and less likely to review them [",
"      <a class=\"abstract\" href=\"UTD.htm?19/29/19927/abstract/28\">",
"       28",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Other contributory factors: emotional turmoil, childhood sexual abuse, troubled relationships with significant persons, and naivete about medical matters [",
"      <a class=\"abstract\" href=\"UTD.htm?19/29/19927/abstract/6,7,29,30\">",
"       6,7,29,30",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13130939\">",
"    <span class=\"h2\">",
"     Somatopsychic hypothesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Minor body changes can initiate a false belief in pregnancy in women who tend to misinterpret somatic stimuli [",
"    <a class=\"abstract\" href=\"UTD.htm?19/29/19927/abstract/31\">",
"     31",
"    </a>",
"    ]. In susceptible women, pseudocyesis has occurred in the context of hepatic failure [",
"    <a class=\"abstract\" href=\"UTD.htm?19/29/19927/abstract/32\">",
"     32",
"    </a>",
"    ], systemic lupus erythematosus [",
"    <a class=\"abstract\" href=\"UTD.htm?19/29/19927/abstract/33\">",
"     33",
"    </a>",
"    ], abdominal neoplasia [",
"    <a class=\"abstract\" href=\"UTD.htm?19/29/19927/abstract/34\">",
"     34",
"    </a>",
"    ], hyponatremia [",
"    <a class=\"abstract\" href=\"UTD.htm?19/29/19927/abstract/35\">",
"     35",
"    </a>",
"    ], and cholecystitis [",
"    <a class=\"abstract\" href=\"UTD.htm?19/29/19927/abstract/36\">",
"     36",
"    </a>",
"    ]. It also occurs in some women with schizophrenia when their antipsychotic medications cause amenorrhea [",
"    <a class=\"abstract\" href=\"UTD.htm?19/29/19927/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13130946\">",
"    <span class=\"h2\">",
"     Psychophysiologic hypothesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The psychophysiologic hypothesis is that major depressive disorder or stress, with their concomitant alterations in brain biogenic amines, may be an important initiating event in pseudocyesis, as biogenic amines are involved in the regulation of reproductive hormones [",
"    <a class=\"abstract\" href=\"UTD.htm?19/29/19927/abstract/14,38\">",
"     14,38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13130953\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of pseudocyesis is made in a non-pregnant, non-psychotic woman who believes she is pregnant and exhibits signs and symptoms of pregnancy. The presence of a medical condition that causes endocrine changes excludes the diagnosis, although endocrine changes can be present in women with pseudocyesis.",
"   </p>",
"   <p>",
"    The Diagnostic and Statistical Manual of Mental Disorders includes pseudocyesis under Somatoform Disorder Not Otherwise Specified (NOS) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/29/19927/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An assessment for psychological contributory factors may confirm the diagnosis of pseudocyesis and identify problems amenable to treatment.&nbsp;The table summarizes aspects of the clinical history relevant to this assessment (",
"    <a class=\"graphic graphic_table graphicRef77304 \" href=\"UTD.htm?27/8/27787\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H990723195\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pseudocyesis should be distinguished from other conditions with similar presentations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pregnancy &mdash; A positive urine or serum beta-human chorionic gonadotropin (hCG) test is diagnostic of pregnancy and highly reliable. False positive and negative tests are rare. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/1/39960?source=see_link\">",
"       \"Human chorionic gonadotropin testing\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Abdominal ultrasound provides visual confirmation of the pregnancy and fetal status [",
"      <a class=\"abstract\" href=\"UTD.htm?19/29/19927/abstract/39,40\">",
"       39,40",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Delusion of pregnancy &ndash; This is a false and fixed belief about being pregnant, despite factual evidence to the contrary. As compared to women with pseudocyesis, these women have a relative absence of physical signs suggestive of pregnancy [",
"      <a class=\"abstract\" href=\"UTD.htm?19/29/19927/abstract/28\">",
"       28",
"      </a>",
"      ]. Delusional pregnancy should be suspected in individuals with psychotic disorders.",
"     </li>",
"     <li>",
"      Medical conditions that can produce some of the signs or symptoms of pregnancy. For example, gestational trophoblastic disease (eg, hydatidiform mole) can be associated with all of the signs and symptoms of pregnancy, but a normal fetus and placenta are not present, a persistent corpus luteum cyst can result in a missed period, pituitary tumors can cause amenorrhea and galactorrhea. Abdominal enlargement can be caused by pelvic tumors, Cushing&rsquo;s syndrome, bezoars, bowel obstruction, constipation, inflammatory bowel disease, ascites, organomegaly, aerophagia, and other conditions [",
"      <a class=\"abstract\" href=\"UTD.htm?19/29/19927/abstract/11\">",
"       11",
"      </a>",
"      ]. Some women with pseudocyesis may misinterpret missed menstrual periods related to stress, weight loss, polycystic ovary syndrome, or other factors as a sign of pregnancy.",
"     </li>",
"     <li>",
"      Feigned pregnancy &ndash; This refers to intentional feigning of pregnancy for some specific gain (eg, gaining attention, obtaining leave from work, avoiding punishment, or avoiding responsibility). This is classified as factitious disorder or malingering, the latter when there is a clear external motive, such as financial gain. In a consecutive case series of women with factitious disorder by proxy (women producing or feigning symptoms in their children), 19 percent had pseudocyesis [",
"      <a class=\"abstract\" href=\"UTD.htm?19/29/19927/abstract/41\">",
"       41",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Couvade syndrome &ndash; Couvade syndrome, also known as &ldquo;sympathetic pregnancy,&rdquo; refers to a condition in which someone close to a pregnant woman experiences pregnancy-related physical symptoms, usually towards the end of the pregnancy and during labor and delivery.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13130962\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Controlled trials of treatments for pseudocyesis have not been performed.&nbsp;Data from randomized trials have provided an evidence-based approach to treatment of all somatoform disorders except conversion disorder, the disorder that pseudocyesis most closely resembles [",
"    <a class=\"abstract\" href=\"UTD.htm?19/29/19927/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The following treatment recommendations are based on case reports and clinical experience.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13130969\">",
"    <span class=\"h2\">",
"     Goals of treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment goals include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Insight into their disorder. However, insight may not be a realistic treatment goal for women who rely heavily on denial and somatization as coping skills [",
"      <a class=\"abstract\" href=\"UTD.htm?19/29/19927/abstract/27\">",
"       27",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Disappearance of physical signs and symptoms of pregnancy. Some women with pseudocyesis employ &ldquo;face-saving&rdquo; explanations for why they are no longer pregnant once symptoms have remitted. For example, a woman may maintain that she miscarried, that the baby &ldquo;went to Heaven,&rdquo; or that witchcraft ended the pregnancy [",
"      <a class=\"abstract\" href=\"UTD.htm?19/29/19927/abstract/42,43\">",
"       42,43",
"      </a>",
"      ].&nbsp;If the patient has shown functional improvement (for example, if she has learned to be more assertive with family members, thereby getting her needs met in ways other than by being pregnant), it is not essential to confront these face-saving solutions.",
"     </li>",
"     <li>",
"      Improved social and occupational functioning.",
"     </li>",
"     <li>",
"      Reduced risk of recurrence of pseudocyesis. This is desirable, but may not be achievable.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13130976\">",
"    <span class=\"h2\">",
"     Conveying the diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;A key intervention is to explain the diagnosis to the patient in a way that is therapeutic rather than damaging. In giving up the belief in pregnancy, a patient may be giving up a means of coping with intense emotions",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    of solving a difficult dilemma [",
"    <a class=\"abstract\" href=\"UTD.htm?19/29/19927/abstract/44\">",
"     44",
"    </a>",
"    ]. Having a strong, positive relationship with a clinician can help a woman face this loss, even if the clinical relationship is newly established and short-term [",
"    <a class=\"abstract\" href=\"UTD.htm?19/29/19927/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Conveying the diagnosis empathically can promote acceptance of the diagnosis and can initiate conversations about underlying issues [",
"    <a class=\"abstract\" href=\"UTD.htm?19/29/19927/abstract/27,45\">",
"     27,45",
"    </a>",
"    ]. In some cases, this suffices for the symptoms to remit, and follow-up may help prevent recurrence [",
"    <a class=\"abstract\" href=\"UTD.htm?19/29/19927/abstract/44\">",
"     44",
"    </a>",
"    ]. By comparison, delivering the diagnosis without empathy can lead to depression, agitation, psychosis,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    &ldquo;doctor shopping&rdquo; [",
"    <a class=\"abstract\" href=\"UTD.htm?19/29/19927/abstract/46-48\">",
"     46-48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Effective communication of the diagnosis of pseudocyesis includes [",
"    <a class=\"abstract\" href=\"UTD.htm?19/29/19927/abstract/47\">",
"     47",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Informing a patient about objective results (eg, physical examination",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      laboratory test negative for pregnancy). Point out to the patient that this situation sometimes happens in susceptible individuals under certain circumstances.",
"     </li>",
"     <li>",
"      Conveying that you do not think she is pregnant.",
"     </li>",
"     <li>",
"      Conveying that you want to continue to work with her to understand her condition further.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It is essential to make every effort to avoid an adversarial relationship",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    excessive confrontation. If the patient asserts that she is pregnant after being told she is not, it is important to accept that she is probably not ready to relinquish her belief. Usually the most therapeutic strategy is to refocus attention on arranging a follow-up visit, emphasizing a desire to understand what is happening, and showing interest in the patient&rsquo;s well-being. If the patient returns with repeated or new complaints which she interprets as proof of pregnancy, the clinician should gently repeat the preceding points as often as necessary.",
"   </p>",
"   <p>",
"    It can be helpful to state that menstrual irregularity is common and that it is understandable how a patient may misinterpret some of her signs and symptoms as indicating pregnancy. It can also be useful to explain that this condition (pseudocyesis) sometimes happens in susceptible individuals under certain circumstances.",
"   </p>",
"   <p>",
"    While there is no need to perform unnecessary laboratory tests, ultrasound examinations can be both diagnostic and therapeutic, if well planned. The propensity of these patients to distort reality interferes with the usefulness of sonography in convincing them that they are not pregnant [",
"    <a class=\"abstract\" href=\"UTD.htm?19/29/19927/abstract/27\">",
"     27",
"    </a>",
"    ]. Patients with pseudocyesis can misinterpret ambiguous ultrasound images and believe they see fetal parts. It can be helpful for a clinician to be present during the procedure to elicit the patient&rsquo;s observations and reactions directly, to address misperceptions, and to discuss pregnancy-linked fears and fantasies [",
"    <a class=\"abstract\" href=\"UTD.htm?19/29/19927/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13130983\">",
"    <span class=\"h2\">",
"     Counseling",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with pseudocyesis rarely agree to formal psychotherapy. More often, a patient will agree to continue to see an",
"    <span class=\"nowrap\">",
"     obstetrician/gynecologist",
"    </span>",
"    or midwife, and will accept informal counseling in that context. In such cases, the perinatal care provider can consult with a psychiatrist for guidance [",
"    <a class=\"abstract\" href=\"UTD.htm?19/29/19927/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Counseling for pseudocyesis is generally brief and episode-focused [",
"    <a class=\"abstract\" href=\"UTD.htm?19/29/19927/abstract/27,42\">",
"     27,42",
"    </a>",
"    ]. Patients rarely agree to continue therapy once the acute symptoms and stressors have resolved, even if they are at risk for symptom recurrence or have not yet acquired more versatile coping skills.",
"   </p>",
"   <p>",
"    The process of counseling for pseudocyesis can be summarized as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Establish and maintain an alliance with the patient.",
"     </li>",
"     <li>",
"      Identify internal and external factors that may be contributing to the patient&rsquo;s belief that she is pregnant (",
"      <a class=\"graphic graphic_table graphicRef77304 \" href=\"UTD.htm?27/8/27787\">",
"       table 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Focus the content of sessions on specific, modifiable internal factors, not on the purported pregnancy. The table lists examples of frequently noted factors and strategies that can address them (",
"      <a class=\"graphic graphic_table graphicRef56225 \" href=\"UTD.htm?31/57/32668\">",
"       table 2",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      When modifiable external factors are identified, invite significant family and friends to sessions to work on these factors, if appropriate (",
"      <a class=\"graphic graphic_table graphicRef70027 \" href=\"UTD.htm?21/59/22459\">",
"       table 3",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H999035837\">",
"    <span class=\"h2\">",
"     Intervening with health care providers and health care systems",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treating pseudocyesis requires teamwork across health care disciplines and systems.&nbsp;A mental health professional, primary care provider, or obstetrical provider can take the lead in forming a coordinated care plan, and communicating this plan to all health care professionals involved with the patient.&nbsp;This includes counseling ultrasound technicians, phlebotomists, clinic receptionists, nurses, and others who may encounter the patient, so that health care personnel do not inadvertently reinforce the false belief in pregnancy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13132246\">",
"    <span class=\"h2\">",
"     Psychotropic medication",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no evidence that psychotropic medication directly treats pseudocyesis; however, when pseudocyesis is accompanied by symptoms of depression, mania,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    psychosis, case reports suggest that treating co-morbid psychiatric symptoms with antidepressants, mood stabilizers,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    antipsychotic agents can alleviate pseudocyesis [",
"    <a class=\"abstract\" href=\"UTD.htm?19/29/19927/abstract/48-50\">",
"     48-50",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/8/40074?source=see_link\">",
"     \"Initial treatment of depression in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/8/38026?source=see_link\">",
"     \"Bipolar disorder in adults: Pharmacotherapy for acute mania, mixed episodes, and hypomania\"",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    In some cases, psychotropic medication may contribute to the maintenance of pseudocyesis by causing side effects that mimic pregnancy symptoms, such as nausea, weight gain, constipation, galactorrhea, and amenorrhea [",
"    <a class=\"abstract\" href=\"UTD.htm?19/29/19927/abstract/28\">",
"     28",
"    </a>",
"    ]. Switching to agents that do not cause these side effects can alleviate pseudocyesis for some patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/24/7562?source=see_link\">",
"     \"First-generation antipsychotic medications: Pharmacology, administration, and comparative side effects\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/10/15530?source=see_link\">",
"     \"Second-generation antipsychotic medications: Pharmacology, administration, and comparative side effects\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13132277\">",
"    <span class=\"h2\">",
"     Restoring menstrual periods",
"    </span>",
"    &nbsp;&mdash;&nbsp;In many cases of pseudocyesis, regular menstrual cycles spontaneously return with psychological acceptance of the non-pregnant state. In some cases, however, ongoing amenorrhea fosters an ongoing belief in pregnancy. Hormonal intervention to induce a withdrawal bleed can promote the patient&rsquo;s ability to relinquish a false belief in pregnancy. If hormonal intervention is done, we suggest prescribing hormonal therapy to accompany rather than precede psychological intervention so vaginal bleeding is not interpreted as a miscarriage [",
"    <a class=\"abstract\" href=\"UTD.htm?19/29/19927/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For women who are not hypoestrogenic, a progestational agent usually will cause withdrawal bleeding (eg,&nbsp;10 mg",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/24/1417?source=see_link\">",
"     medroxyprogesterone acetate",
"    </a>",
"    daily for 10 days). For women with marked hypoestrogenism and amenorrhea, estrogen may be needed along with a progestational agent to obtain withdrawal bleeding (eg, 1.25 mg conjugated estrogen daily for 21 days with 10 mg medroxyprogesterone acetate daily for the last seven days) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/29/19927/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If a woman with pseudocyesis is using a contraceptive agent that can cause amenorrhea (eg, depot",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/24/1417?source=see_link\">",
"     medroxyprogesterone acetate",
"    </a>",
"    injections,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/1/35863?source=see_link\">",
"     etonogestrel",
"    </a>",
"    implant, levonorgestrel-releasing intrauterine device [IUD], extended or continuous use of estrogen-progestin contraceptives), we suggest switching to another method, such as cyclic estrogen-progestin contraceptives, a copper IUD, or nonhormonal methods, if feasible [",
"    <a class=\"abstract\" href=\"UTD.htm?19/29/19927/abstract/51,52\">",
"     51,52",
"    </a>",
"    ]. The patient is less likely to believe she is pregnant if she is having regular menstrual cycles.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13132330\">",
"    <span class=\"h2\">",
"     Involving family and friends",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pseudocyesis is fundamentally a social condition [",
"    <a class=\"abstract\" href=\"UTD.htm?19/29/19927/abstract/47\">",
"     47",
"    </a>",
"    ]. Successful treatment often requires involving significant family members and friends, both to reduce pressures toward pseudocyesis and to help treat pseudocyesis [",
"    <a class=\"abstract\" href=\"UTD.htm?19/29/19927/abstract/14,45,47,53,54\">",
"     14,45,47,53,54",
"    </a>",
"    ].&nbsp;The table lists examples of how family and friends can be involved (",
"    <a class=\"graphic graphic_table graphicRef70027 \" href=\"UTD.htm?21/59/22459\">",
"     table 3",
"    </a>",
"    ). These individuals should be empathic, but not support the patient&rsquo;s belief that she is pregnant, and they should reduce any pressure to become pregnant that they are placing on the patient.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13130997\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pseudocyesis is a somatoform disorder characterized by a false, but non-delusional, belief in being pregnant. (See",
"      <a class=\"local\" href=\"#H13130904\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Abdominal enlargement and other signs and symptoms associated with pregnancy are common in women with pseudocyesis. (See",
"      <a class=\"local\" href=\"#H13130911\">",
"       'Clinical presentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Symptoms generally last from a few weeks to nine months or longer. Recurrences may occur. Prognosis is dependent, to a large extent, on resolution of the specific psychological",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      interpersonal factors that have been involved in the development of pseudocyesis in the patient. (See",
"      <a class=\"local\" href=\"#H13130918\">",
"       'Natural history and prognosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The three major hypotheses about the development of pseudocyesis are the psychosomatic, somatopsychic and psychophysiologic hypotheses. Contributory factors can include psychological pressures, social pressures, and misinterpretations of bodily changes. (See",
"      <a class=\"local\" href=\"#H13130925\">",
"       'Pathogenesis and risk factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of pseudocyesis is made in a non-pregnant, non-psychotic woman who believes she is pregnant and exhibits signs and symptoms of pregnancy. The Diagnostic and Statistical Manual of Mental Disorders includes pseudocyesis under Somatoform Disorder Not Otherwise Specified (NOS). (See",
"      <a class=\"local\" href=\"#H13130953\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Differential diagnosis includes pregnancy, delusional pregnancy, feigned pregnancy, couvade syndrome, and medical disorders that can produce some of the signs or symptoms of pregnancy. (See",
"      <a class=\"local\" href=\"#H990723195\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment goals include disappearance of physical signs and symptoms of pregnancy, improved social and occupational functioning, and reduced risk of recurrence. (See",
"      <a class=\"local\" href=\"#H13130969\">",
"       'Goals of treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Effective communication of the diagnosis of pseudocyesis includes informing a patient about objective results, conveying that you do not think she is pregnant, and conveying that you want to continue to work with her to understand her condition further. It is essential to avoid an adversarial relationship",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      excessive confrontation if the patient is not ready to believe that she is not pregnant. (See",
"      <a class=\"local\" href=\"#H13130976\">",
"       'Conveying the diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Intervention involves conveying the diagnosis empathically, conducting brief supportive counseling with the patient, and advising medical personnel and significant others about helpful ways to support the patient in relinquishing her false belief and refocusing on adaptive goals. Hormonal restoration of menses is sometimes helpful, as is psychopharmacologic treatment of co-morbid psychiatric disorders. (See",
"      <a class=\"local\" href=\"#H999035837\">",
"       'Intervening with health care providers and health care systems'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H13132246\">",
"       'Psychotropic medication'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H13132277\">",
"       'Restoring menstrual periods'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H13132330\">",
"       'Involving family and friends'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 4th ed, American Psychiatric Press, Washington DC 2000.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/29/19927/abstract/2\">",
"      Cohen LM. A current perspective of pseudocyesis. Am J Psychiatry 1982; 139:1140.",
"     </a>",
"    </li>",
"    <li>",
"     Bivin, G, Klinger, M.. Pseudocyesis, Principia Press, Bloomington, Indiana 1937.",
"    </li>",
"    <li>",
"     Koric, E, Vondracek, S, Molnar, S, et al. Pseudocyesis and couvade syndrome. [Cited 12 Dec 2007.] Available from URL: file://www.psitijatrija.com/bibliografija/radoi/koic/Pseudocyesisandcovadesyndrome_.",
"    </li>",
"    <li>",
"     Rosenberg, HK, Coleman, BG, Croop, J et al. Pseudocvesis in an adolescent patient. Clin Pedisatr 1983; 22:708.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/29/19927/abstract/6\">",
"      Hardwick PJ, Fitzpatrick C. Fear, folie and phantom pregnancy: pseudocyesis in a fifteen-year-old girl. Br J Psychiatry 1981; 139:558.",
"     </a>",
"    </li>",
"    <li>",
"     D'Orban, PT. Child stealing and pseudocvesis. BrJ Psvchiatrv 1982; 141:196.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/29/19927/abstract/8\">",
"      Yen SS, Rebar RW, Quesenberry W. Pituitary function in pseudocyesis. J Clin Endocrinol Metab 1976; 43:132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/29/19927/abstract/9\">",
"      Ibekwe PC, Achor JU. Psychosocial and cultural aspects of pseudocyesis. Indian J Psychiatry 2008; 50:112.",
"     </a>",
"    </li>",
"    <li>",
"     Del Pizzo, J, Posey-Bahar, L, Jimenez, R. Pseudocyesis in a teenager with bipolar disorder. Clin Pediatrics 2010; :. [Epub ahead of print].",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/29/19927/abstract/11\">",
"      Del Pizzo J, Del Pizzo J, Posey-Bahar L, Jimenez R. Pseudocyesis in a teenager with bipolar disorder. Clin Pediatr (Phila) 2011; 50:169.",
"     </a>",
"    </li>",
"    <li>",
"     Trivedi, AN, Singh, S: Pseudocyesis and its modern perspective.  Aust NZ J Obstet Gynecol 1998; 38:466.",
"    </li>",
"    <li>",
"     Small, GW. Pseudocyesis: An overview. Can J Psychiatry 1986; 143:452.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/29/19927/abstract/14\">",
"      Starkman MN, Marshall JC, La Ferla J, Kelch RP. Pseudocyesis: psychologic and neuroendocrine interrelationships. Psychosom Med 1985; 47:46.",
"     </a>",
"    </li>",
"    <li>",
"     Brockington, I. Obstetric and gynaecological conditions associated with psychiatric disorder. In: New Oxford Textbook of Psychiatry, Vol 2, Gelder, MG, Lopez-Ibor, JJ, Andreasen, N, (Eds), Oxford University Press Oxford 2000. p.1195.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/29/19927/abstract/16\">",
"      Christodoulou GN. Pseudocyesis. Acta Psychiatr Belg 1978; 78:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/29/19927/abstract/17\">",
"      Silber TJ, Abdalla W. Pseudocyesis in adolescent females. J Adolesc Health Care 1983; 4:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/29/19927/abstract/18\">",
"      Taylor J, Kreeger A. Recurrent pseudocyesis and hypomania. Br J Psychiatry 1987; 151:120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/29/19927/abstract/19\">",
"      Reichenbacher T, Yates A. Pseudocyesis as the presenting symptom in an adolescent patient with an incipient thought disorder. J Adolesc Health Care 1987; 8:456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/29/19927/abstract/20\">",
"      Mortimer A, Banbery J. Pseudocyesis preceding psychosis. Br J Psychiatry 1988; 152:562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/29/19927/abstract/21\">",
"      Goodwin J, Harris D. Suicide in pregnancy: the Hedda Gabler syndrome. Suicide Life Threat Behav 1979; 9:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/29/19927/abstract/22\">",
"      Omer H, Elizur Y, Barnea T, et al. Psychological variables and premature labour: a possible solution for some methodological problems. J Psychosom Res 1986; 30:559.",
"     </a>",
"    </li>",
"    <li>",
"     Tish Davidson, AM. Pseudocyesis. In: Encyclopedia of Mental Disorders. [Cited 11 Dec 2007.] Available from URL: file://www.minddisorders.com/ob-Ps/Pseudocyesis.html.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/29/19927/abstract/24\">",
"      Ladipo OA. An evaluation of 576 hysterosalpingograms on infertile women. Infertility 1979; 2:63.",
"     </a>",
"    </li>",
"    <li>",
"     Barglow, P, Brown, E. Pseudocyesis. In: Modern perspectives in psycho-obstetrics, Howells, JG (Ed), Oliver and Boyd, Edinburgh 1972. p.53.",
"    </li>",
"    <li>",
"     Ouj, U.  Pseudocyesis in a rural southeast Nigerian community.  J Obstet Gynecol Res 2009; 35:660.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/29/19927/abstract/27\">",
"      Starkman MN. Impact of psychodynamic factors on the course and management of patients with pseudocyesis. Obstet Gynecol 1984; 64:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/29/19927/abstract/28\">",
"      Ahuja N, Moorhead S, Lloyd AJ, Cole AJ. Antipsychotic-induced hyperprolactinemia and delusion of pregnancy. Psychosomatics 2008; 49:163.",
"     </a>",
"    </li>",
"    <li>",
"     Marusiae, S, Karloviae, D, Zorieiae, Z et al. Pseudocyesis: A case report. Acta Clin Croatia 2005; 44:291.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/29/19927/abstract/30\">",
"      Hendricks-Matthews MK, Hoy DM. Pseudocyesis in an adolescent incest survivor. J Fam Pract 1993; 36:97, 101.",
"     </a>",
"    </li>",
"    <li>",
"     Pawlowski, EJ, Pawlowski, MMF. Unconscious and abortive aspects of pseudocyesis. Wis Med J 1958; 57.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/29/19927/abstract/32\">",
"      Alfonso CA. Pseudocyesis with concomitant medical illness. Gen Hosp Psychiatry 1990; 12:205.",
"     </a>",
"    </li>",
"    <li>",
"     Hernandez Rodriguez, I, Moreno, MJ, et al: Systemic lupus erythematosus presenting as pseudocyesis. Br J Rheum 1994; 33:400.",
"    </li>",
"    <li>",
"     Echaviz, A: Pseudopregnancy and gastric adenocarcinoma (letter). Medicina Clinica 1984; 83:307.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/29/19927/abstract/35\">",
"      Shutty MS Jr, Leadbetter RA. Case report: recurrent pseudocyesis in a male patient with psychosis, intermittent hyponatremia, and polydipsia. Psychosom Med 1993; 55:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/29/19927/abstract/36\">",
"      Benzick JM. Illusion or hallucination? Cholecystitis presenting as pseudopregnancy in schizophrenia. Psychosomatics 2000; 41:450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/29/19927/abstract/37\">",
"      Seeman MV. Antipsychotic-induced amenorrhea. J Ment Health 2011; 20:484.",
"     </a>",
"    </li>",
"    <li>",
"     Brown E, Barglow P. Pseudocyesis: a paradigm for psychophysiological interactions. Arch Gen Psvchiatry 1971; 24:221.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/29/19927/abstract/39\">",
"      Paulman PM, Sadat A. Pseudocyesis. J Fam Pract 1990; 30:575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/29/19927/abstract/40\">",
"      Kroenke K. Efficacy of treatment for somatoform disorders: a review of randomized controlled trials. Psychosom Med 2007; 69:881.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/29/19927/abstract/41\">",
"      Bass C, Jones D. Psychopathology of perpetrators of fabricated or induced illness in children: case series. Br J Psychiatry 2011; 199:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/29/19927/abstract/42\">",
"      Whelan CI, Stewart DE. Pseudocyesis--a review and report of six cases. Int J Psychiatry Med 1990; 20:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/29/19927/abstract/43\">",
"      Dafallah SE. Pseudocyesis and infertility. Saudi Med J 2004; 25:964.",
"     </a>",
"    </li>",
"    <li>",
"     Murray, JL, Abraham, GE: Pseudocyesis: a review.  Obstet Gyneecol 1978; 51:627.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/29/19927/abstract/45\">",
"      Devane GW, Vera MI, Buhi WC, Kalra PS. Opioid peptides in pseudocyesis. Obstet Gynecol 1985; 65:183.",
"     </a>",
"    </li>",
"    <li>",
"     Drife, JO: Phantom pregnancy.  Br Med J 1985; 291:687.",
"    </li>",
"    <li>",
"     O&rsquo;Grady, JP, Rosenthal, M.  Pseudocyesis: a modern perspective on an old disorder.  Obstet Gynecol Survey 1988; 44:500",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/29/19927/abstract/48\">",
"      Snyder S, Reyner A, Schmeidler J, et al. Prevalence of mental disorders in newly admitted medical inpatients with AIDS. Psychosomatics 1992; 33:166.",
"     </a>",
"    </li>",
"    <li>",
"     Harland, RF, Warner, NJ: Delusions of pregnancy in the elderly.  Int J Geriatric Psychiatry 1997; 12:115.",
"    </li>",
"    <li>",
"     Mendhekar, D, Lohia, D, Jiioha, RC: Pseudocyesis in a pre-pubertal girl (letter). Ind J Pediatr 2010; 77:216.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/29/19927/abstract/51\">",
"      Flanagan PJ, Harel Z. Pseudocyesis in an adolescent using the long-acting contraceptive Depo-Provera. J Adolesc Health 1999; 25:238.",
"     </a>",
"    </li>",
"    <li>",
"     Ayakannu, T, Wordsworth, S, Smith, R, Raghunandan, R, Vine, S.  Pseudocyesis in a teenager using long-term contraception.  J Obstet Gynecol 2007; 27:322.",
"    </li>",
"    <li>",
"     Marusic, S, Karlovic, D, Zoricic, Z, Martinac, M, Jokanovic, L.  Pseudocyesis: a case report.  Acta Clin Croat 2005; 44:291.",
"    </li>",
"    <li>",
"     Ibekwe, PC, Achore JU.  Psychosocial and cultural aspects of pseudocyesis.  Ind J Psychiatry 2008; 50:112.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 14201 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-83.177.194.223-4E972C53F8-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_29_19927=[""].join("\n");
var outline_f19_29_19927=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H13130997\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13130904\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H977486891\">",
"      PREVALENCE AND EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13130911\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H977486860\">",
"      Laboratory",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13130918\">",
"      NATURAL HISTORY AND PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13130925\">",
"      PATHOGENESIS AND RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13130932\">",
"      Psychosomatic hypothesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13130939\">",
"      Somatopsychic hypothesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13130946\">",
"      Psychophysiologic hypothesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13130953\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H990723195\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13130962\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13130969\">",
"      Goals of treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13130976\">",
"      Conveying the diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13130983\">",
"      Counseling",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H999035837\">",
"      Intervening with health care providers and health care systems",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13132246\">",
"      Psychotropic medication",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13132277\">",
"      Restoring menstrual periods",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13132330\">",
"      Involving family and friends",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13130997\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/14201\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/14201|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?27/8/27787\" title=\"table 1\">",
"      History taking in women with pseudocyesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?31/57/32668\" title=\"table 2\">",
"      Counseling women with pseudocyesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?21/59/22459\" title=\"table 3\">",
"      Involving family and friends in pseudocyesis treatment",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/8/38026?source=related_link\">",
"      Bipolar disorder in adults: Pharmacotherapy for acute mania, mixed episodes, and hypomania",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/24/7562?source=related_link\">",
"      First-generation antipsychotic medications: Pharmacology, administration, and comparative side effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/1/39960?source=related_link\">",
"      Human chorionic gonadotropin testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/8/40074?source=related_link\">",
"      Initial treatment of depression in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/10/15530?source=related_link\">",
"      Second-generation antipsychotic medications: Pharmacology, administration, and comparative side effects",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_29_19928="Developmental and behavioral screening tests in primary care";
var content_f19_29_19928=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Developmental and behavioral screening tests in primary care",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/29/19928/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/29/19928/contributors\">",
"     Angela LaRosa, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/29/19928/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/29/19928/contributors\">",
"     Carolyn Bridgemohan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/29/19928/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/29/19928/contributors\">",
"     Mary M Torchia, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?19/29/19928/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 2, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is estimated that 16 percent of children have a developmental",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    behavioral disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?19/29/19928/abstract/1\">",
"     1",
"    </a>",
"    ]. However, only 30 percent are identified before school entrance [",
"    <a class=\"abstract\" href=\"UTD.htm?19/29/19928/abstract/2\">",
"     2",
"    </a>",
"    ]. Children who are detected after school entrance miss the opportunity to participate in early interventions services.",
"   </p>",
"   <p>",
"    To improve the early identification of children with developmental disability, the American Academy of Pediatrics (AAP) recommends that all infants and young children be screened for developmental delays [",
"    <a class=\"abstract\" href=\"UTD.htm?19/29/19928/abstract/3\">",
"     3",
"    </a>",
"    ]. They recommend performing developmental surveillance at every well-child visit and using formal, standardized screening tools at select age intervals (9, 18, and 24 or 30 months) and if developmental concerns are raised by the parent or provider during surveillance (",
"    <a class=\"external\" href=\"file://pediatrics.aappublications.org/cgi/content/full/118/1/405/F1\">",
"     pediatrics.aappublications.org/cgi/content/full/118/1/405/F1",
"    </a>",
"    ). Developmental screening and surveillance in the preschool and school-age child were not addressed in the above document [",
"    <a class=\"abstract\" href=\"UTD.htm?19/29/19928/abstract/3\">",
"     3",
"    </a>",
"    ]. It is our recommendation that screening be performed at the three-year well-child visit and annually thereafter.",
"   </p>",
"   <p>",
"    Selected screening measures that are brief, accurate, and easy to administer and score are available to assist primary care providers in the early detection of developmental and behavioral disorders. These measures will be discussed below, after a brief overview of desirable qualities of screening tests. The process and outcome of developmental surveillance and screening are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/49/26394?source=see_link\">",
"     \"Developmental-behavioral surveillance and screening in primary care\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     SCREENING TESTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Screening is defined as a brief, formal, standardized evaluation, the purpose of which is the early identification of patients with",
"    <strong>",
"     unsuspected",
"    </strong>",
"    deviations from normal. A screening instrument enables detection of",
"    <span class=\"nowrap\">",
"     conditions/concerns",
"    </span>",
"    that may not be readily apparent without screening. Screening does not provide a diagnosis; it helps to determine whether additional investigation (eg, a diagnostic evaluation) by clinicians with special expertise in developmental pediatrics is necessary [",
"    <a class=\"abstract\" href=\"UTD.htm?19/29/19928/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is a common misconception that screening tests are too difficult or too long to administer. Several validated developmental and behavioral screening instruments that are easily and briefly administered are discussed below. The ideal screening test should have established psychometric qualities (ie, validity, reliability, accuracy), be easy to perform and interpret, inexpensive, and acceptable to the child and parents [",
"    <a class=\"abstract\" href=\"UTD.htm?19/29/19928/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Screening tests should be used only for their specified purpose (ie, the early identification of patients with unsuspected deviations from normal) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/29/19928/abstract/4\">",
"     4",
"    </a>",
"    ]. Screening tests also should only be used as designed (eg, with adherence to the standard wording of questions, scoring, and decision making) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/29/19928/abstract/6\">",
"     6",
"    </a>",
"    ]. Violating test standardization decreases the test validity and increases the chance of underdetection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Test characteristics",
"    </span>",
"    &nbsp;&mdash;&nbsp;To minimize underdetection and overreferral, a developmental screening test should be as accurate as possible (that is, it should detect as many children with",
"    <span class=\"nowrap\">",
"     developmental/behavioral",
"    </span>",
"    disability, and exclude as many children without",
"    <span class=\"nowrap\">",
"     developmental/behavioral",
"    </span>",
"    disability, as possible) (",
"    <a class=\"graphic graphic_table graphicRef55297 \" href=\"UTD.htm?0/18/299\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The most common terms used to describe the accuracy of a diagnostic test are sensitivity and specificity (",
"    <a class=\"graphic graphic_table graphicRef77832 \" href=\"UTD.htm?7/50/7979\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sensitivity is the characteristic of a screening test that describes the proportion of children who actually have the condition who have a positive screening test (",
"      <a class=\"graphic graphic_table graphicRef77832 \" href=\"UTD.htm?7/50/7979\">",
"       table 2",
"      </a>",
"      ) (eg, the proportion of children with developmental disability that the test correctly identifies). A developmental screening instrument should correctly identify 70 to 80 percent of children with developmental disabilities at a single administration (ie, should have a sensitivity of 70 to 80 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?19/29/19928/abstract/5\">",
"       5",
"      </a>",
"      ]. Screening tests that detect more than 70 to 80 percent of children with \"true\" developmental disabilities (ie, true positives) also will detect an increasing number of children without \"true\" developmental disabilities (ie, false positives), leading to overreferral.",
"     </li>",
"     <li>",
"      Specificity refers to the proportion of individuals who do not actually have the condition who test negative for the condition (",
"      <a class=\"graphic graphic_table graphicRef77832 \" href=\"UTD.htm?7/50/7979\">",
"       table 2",
"      </a>",
"      ) (eg, the proportion of children without developmental disability that the test correctly identifies). A developmental screening test should correctly identify approximately 80 percent of children without developmental disabilities (ie, should have a specificity of approximately 80 percent). Screening tests that correctly identify more than 80 percent of children without developmental disabilities (ie, true negatives) also will fail to identify an increasing number of children with \"true\" developmental disabilities (ie, false negatives), leading to underdetection and underreferral.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Additional qualities that are desirable in screening tests include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The test should be standardized in a large nationally representative sample of individuals whose characteristics reflect those of the general population",
"     </li>",
"     <li>",
"      The test should be reliable (repeated measurements of a stable phenomenon should fall closely together)",
"     </li>",
"     <li>",
"      The test should be valid (observations should reflect the \"truth\" of the phenomenon being measured)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These terms and other terms used to describe screening tests are discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/18/22823?source=see_link\">",
"     \"Glossary of common biostatistical and epidemiological terms\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     DEVELOPMENTAL SCREENING TESTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are several brief and accurate developmental screening tests that make use of information provided by the parents or direct observation or elicitation of developmental skills. Additional factors to consider when choosing a developmental screening test for use in primary care practice include ease of administration, cost, and time needed for scoring and interpretation skills (",
"    <a class=\"graphic graphic_table graphicRef67290 \" href=\"UTD.htm?3/14/3309\">",
"     table 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef62434 \" href=\"UTD.htm?39/51/40763\">",
"     table 4",
"    </a>",
"    ). The screening tests listed in the tables and discussed below have been shown to be able to correctly identify 70 to 80 percent of children with and without developmental disabilities.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Parent report screens",
"    </span>",
"    &nbsp;&mdash;&nbsp;Screening tests that draw on information that is reported by the parents may be more suitable for primary care than those that require direct observation or elicitation of developmental skills. Such tests can be self-administered in waiting or examination rooms, attached to an appointment letter, administered online before an appointment, or delivered by interview in person or over the telephone. Such tests are usually less expensive, take only a few minutes of professional time to interpret, eliminate the challenge of directly eliciting skills from children who, for whatever reason (illness, sleepiness, anxiety, fear), may not demonstrate their best effort on the day of testing [",
"    <a class=\"abstract\" href=\"UTD.htm?19/29/19928/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. In addition, parent-report screening tests provide a family-focused and collaborative approach to monitoring development and addressing developmental problems [",
"    <a class=\"abstract\" href=\"UTD.htm?19/29/19928/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Selected brief, general developmental screening tests that make use of information provided by the parents and that correctly identify 70 to 80 percent of children with and without developmental disabilities are described below (",
"    <a class=\"graphic graphic_table graphicRef67290 \" href=\"UTD.htm?3/14/3309\">",
"     table 3",
"    </a>",
"    ). Tests that limit screening to one stream (eg, gross motor) are not included. Asking parents whether they would like to complete the parent-report screening form or to have someone go through it with them can minimize incomplete, incorrect, or non-returned forms. In addition, it provides an alternative for parents who are unable to read or are uncomfortable with their reading or language skills.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ages and Stages Questionnaires (ASQ) &ndash; The Ages and Stages Questionnaires (ASQ, formerly the Infant Monitoring System) can be used to screen development in children from 4 to 60 months [",
"      <a class=\"abstract\" href=\"UTD.htm?19/29/19928/abstract/6\">",
"       6",
"      </a>",
"      ]. The ASQ is written at a 3rd- to 12th-grade reading level and is available in English, Spanish, French, and Korean. Parents report the child's developmental skills on 25 to 35 items; it takes about 15 minutes to administer if an interview is required. The ASQ generates a",
"      <span class=\"nowrap\">",
"       pass/fail",
"      </span>",
"      score in four developmental domains: cognitive, motor, self-help, and language. Administration of the ASQ: Social Emotional is recommended when children fail in any domain of the ASQ. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Behavioral screening tests'",
"      </a>",
"      below.)",
"      <br/>",
"      <br/>",
"      In validation studies with standardized measures, the ASQ correctly identified 72 percent of children with developmental delay (range 51 percent at 4 months to 90 percent at 36 months) [",
"      <a class=\"abstract\" href=\"UTD.htm?19/29/19928/abstract/10\">",
"       10",
"      </a>",
"      ]. It also correctly identified 86 percent of children without developmental delay (range 81 percent at 16 months to 92 percent at 36 months) [",
"      <a class=\"abstract\" href=\"UTD.htm?19/29/19928/abstract/10,11\">",
"       10,11",
"      </a>",
"      ]. Additional validation studies have found sensitivities ranging from 87 to 100 percent and specificities ranging from 82 to 93 percent for detection of severe developmental delay, depending upon the gold standard and age of evaluation [",
"      <a class=\"abstract\" href=\"UTD.htm?19/29/19928/abstract/12,13\">",
"       12,13",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      In a study of 334 children (12 to 60 months) presenting to a primary care clinic, the ASQ correctly identified 82 percent of children with and 78 percent of children without developmental delay using a gold standard diagnostic evaluation by a psychologist (Bayley Scales of Infant Development or the Wechsler Preschool and Primary Scale of Intelligence; the Preschool Language Scale; and the Vineland Adaptive Behavior Scales) [",
"      <a class=\"abstract\" href=\"UTD.htm?19/29/19928/abstract/14\">",
"       14",
"      </a>",
"      ]. The ASQ had moderate sensitivity and specificity across age subgroups.",
"     </li>",
"     <li>",
"      Brigance Screens-II &ndash; The Brigance Screens-II can be used to screen development in children from 0 to 90 months. It consists of nine separate forms, one for each 12-month age range, each of which takes 10 to 15 minutes to administer [",
"      <a class=\"abstract\" href=\"UTD.htm?19/29/19928/abstract/6\">",
"       6",
"      </a>",
"      ]. The Brigance Screens-II uses a parent report in the 0- to 24-month age range and direct observation for older children. It is described in greater detail below.",
"     </li>",
"     <li>",
"      Infant-Toddler Checklist for Language and Communications &ndash; The Infant-Toddler Checklist for Language and Communications is part of the Communication and Symbolic Behavior Scales Developmental Profile (CSBS DP) and can be used to screen development in children 6 to 24 months of age [",
"      <a class=\"abstract\" href=\"UTD.htm?19/29/19928/abstract/6\">",
"       6",
"      </a>",
"      ]. It is written at a sixth-grade reading level and is available in English. Parents complete a checklist of 24 questions; it takes about 5 to 10 minutes to administer. Although the Infant-Toddler Checklist for Language and Communications screens only language and communication milestones, it can be used as a general developmental screen because delays in language development often are the first sign of atypical development. The Infant-Toddler Checklist identifies cut-off scores at 1.25 standard deviations below the mean. It correctly identifies 78 percent of children with language delays and 84 percent of children without developmental delays [",
"      <a class=\"abstract\" href=\"UTD.htm?19/29/19928/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Parents' Evaluations of Developmental Status (PEDS) &ndash; The Parents' Evaluations of Developmental Status (PEDS) can be used to screen development in children from birth to eight years. It is written at a fifth-grade reading level and is available in multiple languages, including English, Spanish, French, Portuguese, Chinese, Taiwanese, Vietnamese, Thai, and Somali [",
"      <a class=\"abstract\" href=\"UTD.htm?19/29/19928/abstract/3,6\">",
"       3,6",
"      </a>",
"      ]. It includes 10 questions and takes about two minutes to administer if an interview is required [",
"      <a class=\"abstract\" href=\"UTD.htm?19/29/19928/abstract/6\">",
"       6",
"      </a>",
"      ]. In addition to functioning as a screening test, the PEDS provides longitudinal surveillance and triage. The scoring system identifies children as low, moderate, or high risk for various kinds of disabilities and delays and helps to determine when referrals are necessary and when patient education, in-office counseling, watchful waiting, or additional screening is needed [",
"      <a class=\"abstract\" href=\"UTD.htm?19/29/19928/abstract/15\">",
"       15",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      The PEDS prompts providers to use their clinical observations and knowledge of the child's medical history and family psychosocial status when deciding what kinds of services are needed. The PEDS detects 74 to 79 percent of children with developmental delays and correctly identifies 70 to 80 percent of children without developmental delays [",
"      <a class=\"abstract\" href=\"UTD.htm?19/29/19928/abstract/6,16\">",
"       6,16",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      In a study of 334 children (12 to 60 months) presenting to a primary care clinic, the PEDS correctly identified 74 percent of children with and 64 percent of children without developmental delay using a gold standard diagnostic evaluation by a psychologist (Bayley Scales of Infant Development or the Wechsler Preschool and Primary Scale of Intelligence; the Preschool Language Scale; and the Vineland Adaptive Behavior Scales) [",
"      <a class=\"abstract\" href=\"UTD.htm?19/29/19928/abstract/14\">",
"       14",
"      </a>",
"      ]. The PEDS had moderate sensitivity and specificity for children &le;30 months.",
"      <br/>",
"      <br/>",
"      PEDS: Developmental Milestones (PEDS:DM) is for children from birth to eight years of age and takes about five minutes to complete. The PEDS:DM is six to eight questions per encounter that assess children's skills in each domain (fine and gross motor, receptive and expressive language, self-help, social-emotional, and",
"      <span class=\"nowrap\">",
"       academic/pre-academic).",
"      </span>",
"      It is administered by parent-report but also can be administered directly to children. A one-page longitudinal monitoring form remains in the child's record. The PEDS:DM can be used in conjunction with the PEDS to comply with the AAP's policy statement on screening and surveillance [",
"      <a class=\"abstract\" href=\"UTD.htm?19/29/19928/abstract/3\">",
"       3",
"      </a>",
"      ]. The PEDS:DM detects 79 to 86 percent of children with developmental delays and correctly identifies 75 to 90 percent of children with typical development across domains [",
"      <a class=\"abstract\" href=\"UTD.htm?19/29/19928/abstract/17,18\">",
"       17,18",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Direct elicitation screens",
"    </span>",
"    &nbsp;&mdash;&nbsp;Screening tests that rely on direct observation or elicitation of skill may require several attempts to optimize test conditions [",
"    <a class=\"abstract\" href=\"UTD.htm?19/29/19928/abstract/19\">",
"     19",
"    </a>",
"    ]. If the testing atmosphere is suboptimal (eg, patient is not cooperative, tired, etc.), it is reasonable to have the patient return sooner than the next scheduled health supervision visit for repeat administration. However, if the test atmosphere is suboptimal",
"    <strong>",
"     and",
"    </strong>",
"    there are parent or provider concerns, referral for further evaluation should not be delayed; in such cases, repeating screening to optimize test conditions may delay provision of necessary services.",
"   </p>",
"   <p>",
"    Tests involving direct observation or elicitation of skills require more time than tests that rely on parent report and may not be adequately reimbursed if performed by the primary care provider. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/49/26394?source=see_link&amp;anchor=H1873091#H1873091\">",
"     \"Developmental-behavioral surveillance and screening in primary care\", section on 'Coding and billing'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Direct elicitation screening tests typically are used by pediatric healthcare providers who have a particular interest in developmental problems [",
"    <a class=\"abstract\" href=\"UTD.htm?19/29/19928/abstract/5\">",
"     5",
"    </a>",
"    ]. Direct elicitation screening tests may be used as the only screening test, to complement the results of parent-report instruments, or to explore an area of concern in greater depth (eg, gross motor skills) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/29/19928/abstract/5\">",
"     5",
"    </a>",
"    ]. Many healthcare providers who use direct elicitation screening tests find that it enhances their relationship with the family and child and provides valuable information to make appropriate referrals.",
"   </p>",
"   <p>",
"    Selected brief, general developmental screening tests that make use of direct observation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    elicitation of skills and that correctly identify 70 to 80 percent of children with and without developmental disabilities are described below (",
"    <a class=\"graphic graphic_table graphicRef62434 \" href=\"UTD.htm?39/51/40763\">",
"     table 4",
"    </a>",
"    ). Tests that limit screening to one stream (eg, gross motor) are not included.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Bayley Infant Neurodevelopmental Screener (BINS) &ndash; The Bayley Infant Neurodevelopmental Screener (BINS) can be used to screen development in children 3 to 25 months. It uses 10 to 13 directly elicited items per three- to six-month age range to assess neurologic processes (reflexes and tone), neurodevelopmental skills (fine motor, language), and cognitive processes. It categorizes performance into low, moderate, or high risk via cut scores and provides subtest cut scores for each domain. The BINS detects 75 to 86 percent of children with neurodevelopmental problems and correctly identifies 75 to 86 percent of children without such conditions [",
"      <a class=\"abstract\" href=\"UTD.htm?19/29/19928/abstract/6,20\">",
"       6,20",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Brigance Screens-II &ndash; The Brigance Screens-II can be used to screen development in children from 0 to 90 months. It consists of nine separate forms, one for each 12-month age range, each of which takes 10 to 15 minutes to administer. It uses parent report (in the 0- to 24-month age range), direct observation, and elicitation to assess speech-language, motor skills, and general knowledge at younger ages and reading and math at older ages. The scoring system provides cut-off quotients (which determine the need for further evaluation), percentiles, and age-equivalent scores in various domains and overall. The Brigance Screens-II identifies 70 to 82 percent of children with giftedness or developmental and academic problems, and correctly identifies 70 to 82 percent of children without such conditions [",
"      <a class=\"abstract\" href=\"UTD.htm?19/29/19928/abstract/6,21\">",
"       6,21",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Denver Developmental Screening Test-II (DDST-II) &ndash; The DDST-II is a directly administered tool that is designed to screen expressive and receptive language, gross motor, fine motor, and personal-social skills in children zero to six years of age [",
"      <a class=\"abstract\" href=\"UTD.htm?19/29/19928/abstract/22\">",
"       22",
"      </a>",
"      ]. English and Spanish versions are available. It takes 10 to 20 minutes to administer. The results indicate a risk category (normal, questionable, abnormal).",
"      <br/>",
"      <br/>",
"      In a study comparing the performance of the DDST-II to individual measures of intelligence, speech-language, achievement, and adaptive behavior in 104 children (3 to 72 months), the DDST-II correctly identified 83 percent of children with neurodevelopmental problems, but specificity was limited at 43 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?19/29/19928/abstract/23\">",
"       23",
"      </a>",
"      ]. When children with questionable results are grouped with normals (a more common approach), sensitivity drops to 56 percent and specificity rises to 80 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?19/29/19928/abstract/6\">",
"       6",
"      </a>",
"      ]. Although the DDST-II has been the most widely used developmental assessment tool in pediatrics, it was not intended to identify developmental delay in asymptomatic children (ie, as a screening test in the most traditional sense), but rather to demonstrate the rate of achievement of milestones, with the results interpreted in the context of the child's overall functioning and circumstance (ie, to aid in making skilled observations for developmental surveillance) [",
"      <a class=\"abstract\" href=\"UTD.htm?19/29/19928/abstract/22,24\">",
"       22,24",
"      </a>",
"      ]. Research suggests that its use as a screen will lead to either under- or overdetection [",
"      <a class=\"abstract\" href=\"UTD.htm?19/29/19928/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     BEHAVIORAL SCREENING TESTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of broad-band behavioral screening instruments in primary care practice may facilitate detection of developmental, as well as behavioral problems. Children with undetected developmental problems often present with behavioral issues [",
"    <a class=\"abstract\" href=\"UTD.htm?19/29/19928/abstract/25-27\">",
"     25-27",
"    </a>",
"    ]. Temper tantrums or disruptive behavior, as an example, may be the manifestation of frustration in communication for a child with language delay. Developmental delays should be excluded before screening for behavioral problems.",
"   </p>",
"   <p>",
"    Behavioral screening tests may be broadly or narrowly focused. Broad-band behavioral screens rely on parent- , teacher-, or child-completed questionnaires that, when scored, have subsets that include multiple mental health categories to rule out a broad range of possible diagnoses. Narrow-band behavioral screens are directed toward a specific diagnosis (eg, autism, attention deficit hyperactivity disorder [ADHD]). For screening purposes, broad-band screening should precede narrow-band screening.",
"   </p>",
"   <p>",
"    Behavioral screening instruments have the same desirable characteristics as developmental screening tests: they should be accurate, reliable, and valid. Behavioral screening tests that can correctly identify 70 to 80 percent of children with and without behavioral problems are listed below. Some of the behavior-screening instruments provide both developmental and behavioral screening. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Test characteristics'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Interpretation of behavioral screening tests take into consideration that instruments that rely on parent report may yield false-negative results if the parent does not perceive the behavior as problematic [",
"    <a class=\"abstract\" href=\"UTD.htm?19/29/19928/abstract/28\">",
"     28",
"    </a>",
"    ]. Behavioral screening is meant to identify children who need further evaluation and assessment rather than to provide a diagnosis. Because screening presupposes there is a system in place for following up appropriately when a problem is identified, it is helpful to have a collaborative relationship with one or more mental health professionals in the community.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Broad-band instruments",
"    </span>",
"    &nbsp;&mdash;&nbsp;Broad-band behavioral screens rely on parent- or child-completed questionnaires that, when scored, have subsets that include multiple mental health categories to rule out a broad range of possible diagnoses. Broad-band behavioral screening tests that can correctly identify 70 to 80 percent of children with and without behavioral problems are described below (",
"    <a class=\"graphic graphic_table graphicRef50139 graphicRef63959 \" href=\"UTD.htm?24/61/25565\">",
"     table 5A-B",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ages and Stages Questionnaires: Social Emotional (ASQ:SE) &ndash; The ASQ:SE can be used as a",
"      <span class=\"nowrap\">",
"       behavioral/emotional",
"      </span>",
"      screen in children 6 to 60 months of age [",
"      <a class=\"abstract\" href=\"UTD.htm?19/29/19928/abstract/6\">",
"       6",
"      </a>",
"      ]. The ASQ:SE is designed to supplement the ASQ at each of eight visits between 6 and 60 months. It is available in English and Spanish. The ASQ:SE consists of 30 items that focus on self-regulation, compliance, communication, adaptive functioning, autonomy, affect, and interaction with people. It takes 10 to 15 minutes to administer if an interview is required, and one to three minutes to score. It generates a single cut-off score to indicate when a referral is needed. The ASQ:SE detects 71 to 85 percent of children with",
"      <span class=\"nowrap\">",
"       behavioral/emotional",
"      </span>",
"      problems and correctly identifies 90 to 98 percent of children without",
"      <span class=\"nowrap\">",
"       behavioral/emotional",
"      </span>",
"      problems [",
"      <a class=\"abstract\" href=\"UTD.htm?19/29/19928/abstract/29\">",
"       29",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Brief Infant-Toddler Social-Emotional Assessment (BITSEA) &ndash; The Brief-Infant Toddler Social-Emotional Assessment (BITSEA) can be used as a",
"      <span class=\"nowrap\">",
"       behavioral/emotional",
"      </span>",
"      screen in children 12 to 36 months of age. It is written at a fourth- to sixth-grade reading level and is available in English, Spanish, French, Dutch, and Hebrew [",
"      <a class=\"abstract\" href=\"UTD.htm?19/29/19928/abstract/6\">",
"       6",
"      </a>",
"      ]. It consists of 42 items for identifying social-emotional or behavioral problems and delays in competence and takes five to seven minutes to administer if an interview is required. The scoring system, adjusted for age and sex, indicates the presence or absence of problems and competence. The BITSEA detects 80 to 85 percent of children with",
"      <span class=\"nowrap\">",
"       social/emotional/behavioral",
"      </span>",
"      problems and correctly identifies 75 to 80 percent of children without such problems [",
"      <a class=\"abstract\" href=\"UTD.htm?19/29/19928/abstract/30\">",
"       30",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Conners Rating Scale-Revised Long Form (CRS-R) &ndash; The Conners Rating Scale-Revised Long Form (CRS-R) can be used as a",
"      <span class=\"nowrap\">",
"       behavioral/emotional",
"      </span>",
"      screen in children 3 to 17 years. There are three versions: teacher report, parent report, and youth self-report (for ages 12 to 17 years). It is available in English and French and takes about 20 minutes to administer. The scoring system yields seven factor scores:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Cognitive",
"      <span class=\"nowrap\">",
"       problems/inattention",
"      </span>",
"     </li>",
"     <li>",
"      Hyperactivity",
"     </li>",
"     <li>",
"      Oppositional",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       Anxious/shy",
"      </span>",
"     </li>",
"     <li>",
"      Perfectionism",
"     </li>",
"     <li>",
"      Social problems",
"     </li>",
"     <li>",
"      Psychosomatic",
"      <br/>",
"      <br/>",
"      The CRS-R also has several subscales specific to ADHD. The scoring cut-off is tied to the 93rd percentile for each factor. The CRS-R detects 78 to 92 percent of children with",
"      <span class=\"nowrap\">",
"       social/emotional/behavioral",
"      </span>",
"      problems and correctly identifies 84 to 94 percent of children without such problems [",
"      <a class=\"abstract\" href=\"UTD.htm?19/29/19928/abstract/31\">",
"       31",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Eyberg Child Behavior",
"      <span class=\"nowrap\">",
"       Inventory/Sutter-Eyberg",
"      </span>",
"      Student Behavior Inventory &ndash; The Eyberg Child Behavior",
"      <span class=\"nowrap\">",
"       Inventory/Sutter-Eyberg",
"      </span>",
"      Student Behavior Inventory",
"      <span class=\"nowrap\">",
"       (ECBI/SESBI)",
"      </span>",
"      can be used as a",
"      <span class=\"nowrap\">",
"       behavioral/emotional",
"      </span>",
"      screen in children 2 to 16 years of age [",
"      <a class=\"abstract\" href=\"UTD.htm?19/29/19928/abstract/6\">",
"       6",
"      </a>",
"      ]. The",
"      <span class=\"nowrap\">",
"       ECBI/SESBI",
"      </span>",
"      consists of 36 to 38 short statements of common behavior problems. It takes about seven minutes to administer if an interview is required. It generates a single score to suggest referral for behavioral intervention for externalizing problems (conduct, attention, aggression, etc.). Information from screens with lower scores can be used for planning in-office counseling, selecting educational information, and monitoring behavioral progress. The",
"      <span class=\"nowrap\">",
"       ECBI/SESBI",
"      </span>",
"      detects 80 percent of children with disruptive behavior problems and correctly identifies 86 percent of children without disruptive behavior problems [",
"      <a class=\"abstract\" href=\"UTD.htm?19/29/19928/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Parents' Evaluation of Developmental Status (PEDS) &ndash; The PEDS can be used as a",
"      <span class=\"nowrap\">",
"       behavioral/emotional",
"      </span>",
"      screen in children from birth to eight years. It is described above. In children 4.5 years of age and older, the PEDS correctly identified 87 percent of children with and 79 percent of children without mental health problems according to the Eyberg Child Behavior Inventory or the Possible Problems Checklist [",
"      <a class=\"abstract\" href=\"UTD.htm?19/29/19928/abstract/32\">",
"       32",
"      </a>",
"      ]. In children younger than 4.5 years, the PEDS correctly identified 68 percent of children with and 66 percent of children without mental health problems according to the Eyberg Child Behavior Inventory or the Possible Problems Checklist. The forthcoming PEDS:DM also assesses social-emotional development. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Parent report screens'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pediatric Symptom Checklist (PSC) &ndash; The PSC can be used as a",
"      <span class=\"nowrap\">",
"       behavioral/emotional",
"      </span>",
"      screen in children 4 to 16 years of age [",
"      <a class=\"abstract\" href=\"UTD.htm?19/29/19928/abstract/6\">",
"       6",
"      </a>",
"      ]. It consists of 35 short statements of emotional and behavioral problem behaviors including externalizing (eg, conduct, aggression, etc.) and internalizing (eg, depression, anxiety, adjustment, etc.), with responses of \"never,\" \"sometimes,\" or \"often.\" Sample statements include \"Is afraid of new situations\" and \"Does not show feelings\" [",
"      <a class=\"abstract\" href=\"UTD.htm?19/29/19928/abstract/33\">",
"       33",
"      </a>",
"      ]. The PSC takes about seven minutes to administer if an interview is required. Factor scores identify attentional, internalizing, and externalizing problems. Copies of the PSC and information regarding scoring and criteria for referral can be downloaded from Bright Futures:",
"      <a class=\"external\" href=\"file://www.brightfutures.org/mentalhealth/pdf/professionals/ped_sympton_chklst.pdf\">",
"       www.brightfutures.org",
"      </a>",
"      <br/>",
"      <br/>",
"      The Pediatric Symptom Checklist detects 80 to 95 percent of children with",
"      <span class=\"nowrap\">",
"       behavioral/emotional",
"      </span>",
"      problems in most studies and correctly identifies 68 to 100 percent of children without disruptive behavior problems using comprehensive assessments by clinicians",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      other well-validated measures (eg, the Children's Behavior Checklist, the Children's Global Assessment Scale, the Diagnostic Interview for Children and Adolescents) as the gold standard [",
"      <a class=\"abstract\" href=\"UTD.htm?19/29/19928/abstract/33-37\">",
"       33-37",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Narrow-band instruments",
"    </span>",
"    &nbsp;&mdash;&nbsp;Narrow-band behavioral screens are directed toward a specific diagnosis (eg, autism, ADHD) (",
"    <a class=\"graphic graphic_table graphicRef56771 \" href=\"UTD.htm?29/20/30027\">",
"     table 6",
"    </a>",
"    ). For screening purposes, broad-band screening should precede narrow-band screening. Although a complete discussion of the wide range of narrow-band behavioral screening instruments that are available is beyond the scope of this topic review, examples of three that are commonly used in primary care are provided below.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Conners Rating Scale-Revised Short Form (CRS-R) &ndash; The Conners Rating Scale-Revised Short Form screens for symptoms of ADHD: inattention, cognitive problems, hyperactivity, and oppositional behaviors in children 3 to 17 years of age. Cut-offs are tied to the 93rd percentile for each factor. It is described in greater detail above. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Broad-band instruments'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Modified Checklist for Autism in Toddlers (M-CHAT) &ndash; The Modified Checklist for Autism in Toddlers (M-CHAT) is a narrow-band screen for autism that can be used in children 16 to 30 months of age. It is written at a fourth- to sixth-grade reading level and is available in English and Spanish [",
"      <a class=\"abstract\" href=\"UTD.htm?19/29/19928/abstract/6\">",
"       6",
"      </a>",
"      ]. It takes about five minutes to administer. It uses a cut-off based on two of six critical items or any three items from a checklist of 23 items. The test characteristics of the M-CHAT are discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/1/14361?source=see_link\">",
"       \"Screening tools for autism spectrum disorders\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Vanderbilt ADHD Parent Rating Scale (VADPRS) &ndash; The VADPRS is based upon the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV) criteria for ADHD. The internal consistency and factor structure of the VADPRS are acceptable and consistent with DSM-IV and other accepted measures of ADHD. The VADPRS is written slightly below a third-grade reading level. It includes the core symptoms of ADHD, a rating of performance, and a limited screen for common comorbid conditions. The scoring system follows the criteria required to make a DSM-IV diagnosis. The ease of administration and scoring, as well as the inclusion of specific DSM-IV criteria, make the VADPRS a useful clinical and research tool [",
"      <a class=\"abstract\" href=\"UTD.htm?19/29/19928/abstract/38\">",
"       38",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/18/26922?source=see_link&amp;anchor=H189248586#H189248586\">",
"       \"Attention deficit hyperactivity disorder in children and adolescents: Clinical features and evaluation\", section on 'Behavior rating scales'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Screening is defined as a brief, formal, standardized evaluation, the purpose of which is the early identification of patients with unsuspected deviations from normal. The ideal screening test should have established psychometric qualities (ie, validity, reliability, accuracy), be easy to perform and interpret, inexpensive, and acceptable to the child and parents. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Screening tests'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3\">",
"       'Test characteristics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are several brief and accurate developmental screening tests that make use of information provided by the parents (",
"      <a class=\"graphic graphic_table graphicRef67290 \" href=\"UTD.htm?3/14/3309\">",
"       table 3",
"      </a>",
"      ) or direct observation or elicitation of developmental skills (",
"      <a class=\"graphic graphic_table graphicRef62434 \" href=\"UTD.htm?39/51/40763\">",
"       table 4",
"      </a>",
"      ). Screening tests that draw on information that is reported by the parents may be more suitable for primary care than those that require direct observation or elicitation of developmental skills. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Developmental screening tests'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Screening for behavioral problems may facilitate the detection of developmental, as well as behavioral problems. Behavioral screening tests may be broadly or narrowly focused. Broadly focused screens rely on parent-, teacher-, or child-completed questionnaires that, when scored, have subsets that include multiple mental health categories to screen for a broad range of possible diagnoses (",
"      <a class=\"graphic graphic_table graphicRef50139 graphicRef63959 \" href=\"UTD.htm?24/61/25565\">",
"       table 5A-B",
"      </a>",
"      ). Narrowly focused screens are directed toward a specific diagnosis (eg, autism, attention deficit disorder) (",
"      <a class=\"graphic graphic_table graphicRef56771 \" href=\"UTD.htm?29/20/30027\">",
"       table 6",
"      </a>",
"      ). For screening purposes, broad-band screening should precede narrow-band screening. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Behavioral screening tests'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/29/19928/abstract/1\">",
"      Newacheck PW, Strickland B, Shonkoff JP, et al. An epidemiologic profile of children with special health care needs. Pediatrics 1998; 102:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/29/19928/abstract/2\">",
"      Palfrey JS, Singer JD, Walker DK, Butler JA. Early identification of children's special needs: a study in five metropolitan communities. J Pediatr 1987; 111:651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/29/19928/abstract/3\">",
"      Council on Children With Disabilities, Section on Developmental Behavioral Pediatrics, Bright Futures Steering Committee, Medical Home Initiatives for Children With Special Needs Project Advisory Committee. Identifying infants and young children with developmental disorders in the medical home: an algorithm for developmental surveillance and screening. Pediatrics 2006; 118:405.",
"     </a>",
"    </li>",
"    <li>",
"     Meisels SJ, Provence S. Screening and Assessment: Guidelines for Identifying Vulnerable Children and Their Families. National Center for Clinical Infant Programs, Washington, DC 1989.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/29/19928/abstract/5\">",
"      Squires J, Nickel RE, Eisert D. Early detection of developmental problems: strategies for monitoring young children in the practice setting. J Dev Behav Pediatr 1996; 17:420.",
"     </a>",
"    </li>",
"    <li>",
"     Glascoe FP. Collaborating with Parents. Ellsworth &amp; Vandermeer Press, Ltd, Nashville, TN 1998.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/29/19928/abstract/7\">",
"      Glascoe FP, Foster EM, Wolraich ML. An economic analysis of developmental detection methods. Pediatrics 1997; 99:830.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/29/19928/abstract/8\">",
"      Glascoe FP. Screening for developmental and behavioral problems. Ment Retard Dev Disabil Res Rev 2005; 11:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/29/19928/abstract/9\">",
"      Dworkin PH. Detection of behavioral, developmental, and psychosocial problems in pediatric primary care practice. Curr Opin Pediatr 1993; 5:531.",
"     </a>",
"    </li>",
"    <li>",
"     Technical Report on ASQ. Available at: file://www.brookespublishing.com/store/books/squires-asq/asq-technical.pdf (Accessed on October 17, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/29/19928/abstract/11\">",
"      Squires J, Bricker D, Potter L. Revision of a parent-completed development screening tool: Ages and Stages Questionnaires. J Pediatr Psychol 1997; 22:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/29/19928/abstract/12\">",
"      Yu LM, Hey E, Doyle LW, et al. Evaluation of the Ages and Stages Questionnaires in identifying children with neurosensory disability in the Magpie Trial follow-up study. Acta Paediatr 2007; 96:1803.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/29/19928/abstract/13\">",
"      Gollenberg AL, Lynch CD, Jackson LW, et al. Concurrent validity of the parent-completed Ages and Stages Questionnaires, 2nd Ed. with the Bayley Scales of Infant Development II in a low-risk sample. Child Care Health Dev 2010; 36:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/29/19928/abstract/14\">",
"      Limbos MM, Joyce DP. Comparison of the ASQ and PEDS in screening for developmental delay in children presenting for primary care. J Dev Behav Pediatr 2011; 32:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/29/19928/abstract/15\">",
"      Glascoe FP. Early detection of developmental and behavioral problems. Pediatr Rev 2000; 21:272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/29/19928/abstract/16\">",
"      Glascoe FP. Toward a model for an evidenced-based approach to developmental/behavioral surveillance, promotion and patient education. Ambulatory Child Health 1999; 5:197.",
"     </a>",
"    </li>",
"    <li>",
"     Glascoe, FP, Robertshaw, NS. PEDS: Developmental Milestones. Ellsworth &amp; Vandermeer Press, LLC, Nashville, TN 2007.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/29/19928/abstract/18\">",
"      Brothers KB, Glascoe FP, Robertshaw NS. PEDS: developmental milestones--an accurate brief tool for surveillance and screening. Clin Pediatr (Phila) 2008; 47:271.",
"     </a>",
"    </li>",
"    <li>",
"     Blackman JA. Developmental screening: Infants, toddlers, and preschoolers. In: Developmental-Behavioral Pediatrics, 3rd ed, Levine MD, Carey WB, Crocker AC (Eds), WB Saunders, Philadelphia 1999. p.689.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/29/19928/abstract/20\">",
"      Macias MM, Saylor CF, Greer MK, et al. Infant screening: the usefulness of the Bayley Infant Neurodevelopmental Screener and the Clinical Adaptive Test/Clinical Linguistic Auditory Milestone Scale. J Dev Behav Pediatr 1998; 19:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/29/19928/abstract/21\">",
"      Glascoe FP. The Brigance Infant and Toddler Screen: standardization and validation. J Dev Behav Pediatr 2002; 23:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/29/19928/abstract/22\">",
"      Frankenburg WK, Dodds J, Archer P, et al. The Denver II: a major revision and restandardization of the Denver Developmental Screening Test. Pediatrics 1992; 89:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/29/19928/abstract/23\">",
"      Glascoe FP, Byrne KE, Ashford LG, et al. Accuracy of the Denver-II in developmental screening. Pediatrics 1992; 89:1221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/29/19928/abstract/24\">",
"      Dworkin PH. Developmental screening: (still) expecting the impossible? Pediatrics 1992; 89:1253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/29/19928/abstract/25\">",
"      Blackman JA, Cobb LS. A comparison of parents' perceptions of common behavior problems in developmentally at-risk and normal children. Child Health Care 1989; 18:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/29/19928/abstract/26\">",
"      Oberklaid F, Dworkin PH, Levine MD. Developmental-behavioral dysfunction in preschool children. Descriptive analysis of a pediatric consultative model. Am J Dis Child 1979; 133:1126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/29/19928/abstract/27\">",
"      Glascoe FP. It's not what it seems. The relationship between parents' concerns and children with global delays. Clin Pediatr (Phila) 1994; 33:292.",
"     </a>",
"    </li>",
"    <li>",
"     Stancin, T, Perrin, EC. Behavioral screening. In: The Zuckerman Parker Handbook of Developmental and Behavioral Pediatrics for Primary Care, 3rd ed, Augustyn, M, Zuckerman, B, Caronna, EB (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2011. p.44.",
"    </li>",
"    <li>",
"     Squires J, Bricker D, Twombly E. Technical report on ASQ:SE. Available at: www.brookespublishing.com/store/books/squires-asqse/ASQ-SE_TechnicalReport.pdf (Accessed on October 17, 2007).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/29/19928/abstract/30\">",
"      Briggs-Gowan MJ, Carter AS, Irwin JR, et al. The Brief Infant-Toddler Social and Emotional Assessment: screening for social-emotional problems and delays in competence. J Pediatr Psychol 2004; 29:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/29/19928/abstract/31\">",
"      Conners CK, Sitarenios G, Parker JD, Epstein JN. Revision and restandardization of the Conners Teacher Rating Scale (CTRS-R): factor structure, reliability, and criterion validity. J Abnorm Child Psychol 1998; 26:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/29/19928/abstract/32\">",
"      Glascoe FP. Parents' evaluation of developmental status: how well do parents' concerns identify children with behavioral and emotional problems? Clin Pediatr (Phila) 2003; 42:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/29/19928/abstract/33\">",
"      Jellinek MS, Murphy JM. The recognition of psychosocial disorders in pediatric office practice: the current status of the pediatric symptom checklist. J Dev Behav Pediatr 1990; 11:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/29/19928/abstract/34\">",
"      Murphy JM, Reede J, Jellinek MS, Bishop SJ. Screening for psychosocial dysfunction in inner-city children: further validation of the Pediatric Symptom checklist. J Am Acad Child Adolesc Psychiatry 1992; 31:1105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/29/19928/abstract/35\">",
"      Jellinek MS, Murphy JM, Robinson J, et al. Pediatric Symptom Checklist: screening school-age children for psychosocial dysfunction. J Pediatr 1988; 112:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/29/19928/abstract/36\">",
"      Jellinek MS, Murphy JM, Burns BJ. Brief psychosocial screening in outpatient pediatric practice. J Pediatr 1986; 109:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/29/19928/abstract/37\">",
"      Walker WO Jr, LaGrone RG, Atkinson AW. Psychosocial screening in pediatric practice: identifying high-risk children. J Dev Behav Pediatr 1989; 10:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/29/19928/abstract/38\">",
"      Wolraich ML, Lambert W, Doffing MA, et al. Psychometric properties of the Vanderbilt ADHD diagnostic parent rating scale in a referred population. J Pediatr Psychol 2003; 28:559.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 622 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-122.72.76.133-90821EDB07-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_29_19928=[""].join("\n");
var outline_f19_29_19928=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H10\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      SCREENING TESTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Test characteristics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      DEVELOPMENTAL SCREENING TESTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Parent report screens",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Direct elicitation screens",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      BEHAVIORAL SCREENING TESTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Broad-band instruments",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Narrow-band instruments",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/622\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/622|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?0/18/299\" title=\"table 1\">",
"      Definition of accuracy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?7/50/7979\" title=\"table 2\">",
"      Sensitivity specificity PPV NPV",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/14/3309\" title=\"table 3\">",
"      Parent report screens",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?39/51/40763\" title=\"table 4\">",
"      Direct elicitation screens",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?17/34/17964\" title=\"table 5A\">",
"      Broad behavior screens I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?18/20/18764\" title=\"table 5B\">",
"      Broad behavior screens II",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?29/20/30027\" title=\"table 6\">",
"      Narrow behavior screens",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/18/26922?source=related_link\">",
"      Attention deficit hyperactivity disorder in children and adolescents: Clinical features and evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/49/26394?source=related_link\">",
"      Developmental-behavioral surveillance and screening in primary care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/18/22823?source=related_link\">",
"      Glossary of common biostatistical and epidemiological terms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/1/14361?source=related_link\">",
"      Screening tools for autism spectrum disorders",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_29_19929="Unicornuate uter and xtra horn";
var content_f19_29_19929=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F78813%7EOBGYN%2F73807%7EOBGYN%2F61993%7EOBGYN%2F73768%7EOBGYN%2F50733&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F78813%7EOBGYN%2F73807%7EOBGYN%2F61993%7EOBGYN%2F73768%7EOBGYN%2F50733&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Unicornuate uterus with uterine horn (not containing an endometrial cavity) not fused to unicornuate uterus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 383px; height: 322px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Pediatric and Adolescent Gynecology, 6th ed, Emans SJ, Laufer MR (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2012. Copyright &copy; 2012 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Unicornuate uterus with uterine horn (not containing an endometrial cavity) fused to unicornuate uterus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 358px; height: 250px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Pediatric and Adolescent Gynecology, 6th ed, Emans SJ, Laufer MR (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2012. Copyright &copy; 2012 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Unicornuate uterus with noncommunicating uterine horn (containing an endometrial cavity) not fused to unicornuate uterus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 379px; height: 310px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from:&nbsp;Laufer MR. Structural abnormalities of the female reproductive tract. In: Pediatric and adolescent gynecology, 6th ed, Emans SJ, Laufer MR, Goldstein DP (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2012.&nbsp;Copyright &copy; 2012 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Unicornuate uterus with noncommunicating uterine horn (containing an endometrial cavity) fused to unicornuate uterus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 382px; height: 260px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Pediatric and Adolescent Gynecology, 6th ed, Emans SJ, Laufer MR (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2012. Copyright &copy; 2012 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Unicornuate uterus with communicating uterine horn",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 373px; height: 244px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Pediatric and Adolescent Gynecology, 6th ed, Emans SJ, Laufer MR (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2012. Copyright &copy; 2012 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_29_19929=[""].join("\n");
var outline_f19_29_19929=null;
var title_f19_29_19930="Locoregional methods for management and palliation in patients who present with stage IV colorectal cancer";
var content_f19_29_19930=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Locoregional methods for management and palliation in patients who present with stage IV colorectal cancer",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/29/19930/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/29/19930/contributors\">",
"     Miguel A Rodriguez-Bigas, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/29/19930/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/29/19930/contributors\">",
"     Kenneth K Tanabe, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/29/19930/contributors\">",
"     Deputy Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/29/19930/contributors\">",
"     Diane MF Savarese, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/29/19930/contributors\">",
"     Rosemary B Duda, MD, MPH, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?19/29/19930/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 18, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the United States, approximately 20 percent of patients with colorectal cancer (CRC) have metastatic (stage IV, (",
"    <a class=\"graphic graphic_table graphicRef72913 \" href=\"UTD.htm?23/26/23982\">",
"     table 1",
"    </a>",
"    )) disease at the time of diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?19/29/19930/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. Although major advances in systemic chemotherapy have expanded the therapeutic options for these patients and improved median survival from less than one year to 20 months or longer, fewer than 10 percent of those treated with chemotherapy alone are still alive at five years. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/20/21833?source=see_link&amp;anchor=H183911606#H183911606\">",
"     \"Systemic chemotherapy for metastatic colorectal cancer: General principles\", section on 'Chemotherapy versus supportive care'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/20/21833?source=see_link\">",
"     \"Systemic chemotherapy for metastatic colorectal cancer: General principles\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    On the other hand, surgery provides a potentially curative option for selected patients with limited metastatic disease, especially if located in one organ system (such as liver or lung), isolated local recurrence, or limited intraabdominal disease. With aggressive management integrating chemotherapy and surgery, long-term survival can be achieved in as many as 50 percent of cases. In selected patients, even resection of metastases in more than one organ has been successful in achieving long-term survival [",
"    <a class=\"abstract\" href=\"UTD.htm?19/29/19930/abstract/4\">",
"     4",
"    </a>",
"    ]. Aggressive surgical cytoreduction with intraperitoneal chemotherapy has been applied to patients with isolated peritoneal carcinomatosis, but the benefits of this approach remain controversial. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/55/41850?source=see_link\">",
"     \"Management of potentially resectable colorectal cancer liver metastases\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/15/13560?source=see_link\">",
"     \"Surgical resection of pulmonary metastases: Outcomes by histology\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/32/13834?source=see_link\">",
"     \"Surgical resection of pulmonary metastases: Benefits; indications; preoperative evaluation and techniques\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H15\">",
"     'Aggressive cytoreduction and intraperitoneal chemotherapy for peritoneal carcinomatosis'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/37/11866?source=see_link\">",
"     \"Treatment of locally advanced unresectable or recurrent rectal cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/37/11866?source=see_link&amp;anchor=H22#H22\">",
"     \"Treatment of locally advanced unresectable or recurrent rectal cancer\", section on 'Locally recurrent rectal cancer'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Surgical resection may also provide the best option for palliation of symptoms of obstruction and bleeding from the primary tumor in patients who are not candidates for a curative resection.",
"   </p>",
"   <p>",
"    This topic will review the management of the primary tumor (surgical and nonsurgical options) in patients who present with stage IV CRC, and surgical cytoreduction and intraperitoneal chemotherapy for isolated peritoneal carcinomatosis. General surgical principles in patients with primary colon cancer, management of patients with isolated, potentially resectable liver metastases, surgical management of lung metastases, and posttreatment surveillance are discussed in detail elsewhere. (See appropriate topic reviews).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12027618\">",
"    <span class=\"h1\">",
"     OUTCOMES AFTER RESECTION OF ISOLATED METASTATIC DISEASE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h2\">",
"     Limited hepatic and pulmonary metastatic disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, surgery provides a potentially curative option for selected patients with limited metastatic disease. Long-term survival can be achieved with metastasectomy in as many as 50 percent of cases, and an aggressive surgical approach to both the primary and the metastatic sites is warranted, in conjunction with systemic chemotherapy. Management of potentially resectable hepatic metastases (including a discussion as to integration of systemic chemotherapy into the surgical paradigm) and resection of pulmonary metastases are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/55/41850?source=see_link\">",
"     \"Management of potentially resectable colorectal cancer liver metastases\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/15/13560?source=see_link\">",
"     \"Surgical resection of pulmonary metastases: Outcomes by histology\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/32/13834?source=see_link\">",
"     \"Surgical resection of pulmonary metastases: Benefits; indications; preoperative evaluation and techniques\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Isolated adrenal metastases",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adrenal metastases are uncommon (14 percent in one autopsy series [",
"    <a class=\"abstract\" href=\"UTD.htm?19/29/19930/abstract/5\">",
"     5",
"    </a>",
"    ]); isolated adrenal metastases are even more rare. Aggressive surgical resection for isolated adrenal metastases is described in only a few case reports or small series [",
"    <a class=\"abstract\" href=\"UTD.htm?19/29/19930/abstract/6-11\">",
"     6-11",
"    </a>",
"    ]. In the largest series of eight patients with apparently isolated adrenal metastasis from CRC (all of whom underwent \"adjuvant\" chemotherapy), one remained alive and disease-free 12 months after adrenalectomy, one was lost to follow-up, and six died of malignancy. The mean survival of the patients who died was 32 (range 12 to 60) months.",
"   </p>",
"   <p>",
"    In contrast to the situation with isolated adrenal metastases, the development of adrenal metastases after liver resection for CRC liver metastases is associated with a poor prognosis, and adrenalectomy is probably not warranted [",
"    <a class=\"abstract\" href=\"UTD.htm?19/29/19930/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Ovarian metastases",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of ovarian metastases (synchronous or metachronous) in patients with CRC is 1 to 14 percent. They are more common in premenopausal as compared to postmenopausal women, and with colonic rather than rectal primaries [",
"    <a class=\"abstract\" href=\"UTD.htm?19/29/19930/abstract/13\">",
"     13",
"    </a>",
"    ]. While it is generally acknowledged that ovarian metastases (particularly if synchronous and bilateral) represent a poor prognostic factor, complete resection may improve survival [",
"    <a class=\"abstract\" href=\"UTD.htm?19/29/19930/abstract/14,15\">",
"     14,15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Bulky ovarian metastases are often symptomatic and less responsive to systemic chemotherapy than are other sites of disease [",
"    <a class=\"abstract\" href=\"UTD.htm?19/29/19930/abstract/16\">",
"     16",
"    </a>",
"    ]. Resection is associated with fairly low morbidity, and in some cases, may improve quality of life and prolong survival, even in the setting of widespread extraovarian metastatic disease [",
"    <a class=\"abstract\" href=\"UTD.htm?19/29/19930/abstract/17,18\">",
"     17,18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12027710\">",
"    <span class=\"h2\">",
"     Retroperitoneal nodes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Isolated retroperitoneal nodal recurrence occurs in less than 2 percent of patients following a curative-intent colon cancer resection [",
"    <a class=\"abstract\" href=\"UTD.htm?19/29/19930/abstract/19-21\">",
"     19-21",
"    </a>",
"    ]. Salvage surgery had previously been avoided due to the poor prognosis [",
"    <a class=\"abstract\" href=\"UTD.htm?19/29/19930/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]; however, this concept has been challenged. A retrospective review of nine studies, including case reports, case series, and case-control studies, reported a survival benefit and no operative mortality for 110 patients undergoing a salvage retroperitoneal nodal resection [",
"    <a class=\"abstract\" href=\"UTD.htm?19/29/19930/abstract/24\">",
"     24",
"    </a>",
"    ]. The median disease-free survival was 17 to 21 months and the duration of overall survival ranged from 19 months to 18 years (median 34 to 44 months). Local recurrence rates after salvage surgery ranged from 67 to 80 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?19/29/19930/abstract/19-21\">",
"     19-21",
"    </a>",
"    ]. These series were collected over a time when new chemotherapy regimens were being added quickly (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/58/10151?source=see_link\">",
"     cetuximab",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    ). It is unclear if chemotherapy improved the observed survival statistics.&nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     MANAGEMENT OF THE PRIMARY CANCER IN PATIENTS PRESENTING WITH SYNCHRONOUS METASTASES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initial management of the primary site in patients who present with stage IV disease is controversial, and there are no data from prospective randomized studies to guide treatment. In general, the choice and sequence of treatment is guided by the presence or absence of symptoms from the primary tumor and whether or not the metastases are potentially resectable.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6297413\">",
"    <span class=\"h2\">",
"     Surgical issues",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Symptomatic primary",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with a symptomatic primary tumor, the decision to proceed with surgery needs to be individualized depending on the presenting symptoms and signs as well as the extent of the metastatic disease. In general, patients with a perforated tumor need surgery, while for those with bleeding or obstruction, the need for surgery is dependent upon the clinical situation.",
"   </p>",
"   <p>",
"    Although with the newer chemotherapeutic regimens there may be a response in the primary tumor, this response may not be as robust in the primary site as it is in the liver metastases [",
"    <a class=\"abstract\" href=\"UTD.htm?19/29/19930/abstract/25\">",
"     25",
"    </a>",
"    ]. It is imperative to evaluate the primary site periodically in patients with an intact primary tumor while on chemotherapy.",
"   </p>",
"   <p>",
"    If the patient is not a surgical candidate because of comorbidities, high operative risk(s), decreased life expectancy, or refuses surgery, nonsurgical options can be considered. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Nonsurgical palliative options'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Asymptomatic",
"    </span>",
"    &nbsp;&mdash;&nbsp;In practice, the decision to pursue surgical resection of an asymptomatic primary site is based upon the curability of metastatic disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h4\">",
"     Potentially curable metastatic disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;If the metastases are potentially resectable for cure, then an aggressive surgical approach is warranted for both the primary and metastatic sites with the aim of curing the patient. A common sequence is initial systemic chemotherapy to allow early aggressive disease progression to become manifest, followed by reevaluation for surgery. If there is widespread disease progression, resection will likely provide no specific benefit. If, on the other hand, the disease has responded or is stable, resection of both the primary tumor and the metastatic disease could be attempted in either a single or separate operations. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/55/41850?source=see_link&amp;anchor=H18#H18\">",
"     \"Management of potentially resectable colorectal cancer liver metastases\", section on 'Timing of hepatectomy in patients presenting with metastases'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Another consideration that may influence the timing of resection of the primary is that an intact primary tumor may increase the risk of a bowel perforation during treatment with the drug",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    (risk 1 to 2 percent), although at least some data suggest that GI tract perforations in patients receiving bevacizumab, when they occur, rarely involve an intact primary site. However, patients who have undergone resection of their primary tumor may also be at increased risk for surgical site complications associated with use of bevacizumab. In one series, this risk was limited to patients with a rectal (rather than colonic) primary, and to those who had preoperative irradiation; it was particularly high if there was a history of a postoperative anastomotic leak. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/54/43882?source=see_link&amp;anchor=H1651227458#H1651227458\">",
"     \"Toxicity of molecularly targeted antiangiogenic agents: Non-cardiovascular effects\", section on 'Bevacizumab'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Thus, at least for primary colon cancers, initial resection of the primary tumor might be preferred for patients who have either borderline resectable metastases or initially unresectable liver metastases that are potentially resectable after a downstaging response to chemotherapy (an approach termed \"conversion therapy\"). In this setting,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    may be added to initial chemotherapy as it maximizes the chance of responding to an",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    - or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    -containing regimen. However, when bevacizumab is used in the neoadjuvant setting, because of its inhibitory effect on wound healing and its relatively long half life (20 days), at least 28 days (and preferably six to eight weeks) should elapse between the last dose of bevacizumab and major surgery. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/55/41850?source=see_link&amp;anchor=H9#H9\">",
"     \"Management of potentially resectable colorectal cancer liver metastases\", section on 'Conversion therapy for initially unresectable metastases'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/54/43882?source=see_link&amp;anchor=H91044850#H91044850\">",
"     \"Toxicity of molecularly targeted antiangiogenic agents: Non-cardiovascular effects\", section on 'Hepatic metastasectomy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Others have proposed the reverse approach to the liver and the primary tumor, performing postchemotherapy liver resection initially, followed by primary tumor resection [",
"    <a class=\"abstract\" href=\"UTD.htm?19/29/19930/abstract/25\">",
"     25",
"    </a>",
"    ]. Proponents of this approach suggest that since patients with synchronous liver metastases will most likely die from progression of their disease, the liver should be addressed first to avoid delaying treatment of metastatic disease. Additionally, a planned liver resection, especially a technically challenging one, may prove intraoperatively to not be feasible. In such cases, it is better to define this unresectability before committing to resection of the primary tumor and most especially if the primary tumor resection requires an APR. One retrospective series reported similar outcomes comparing the classical approach with other approaches, including the reverse approach to the management of potentially resectable hepatic metastasis [",
"    <a class=\"abstract\" href=\"UTD.htm?19/29/19930/abstract/26\">",
"     26",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h4\">",
"     Incurable metastatic disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;The decision as to whether to resect the primary tumor is more complex for asymptomatic patients who have unresectable metastatic disease; in such patients, the risk to benefit ratio of resecting the primary tumor must be carefully considered. Resecting the primary is not without risk. For patients with metastatic CRC who undergo surgery, there is a 20 to 30 percent risk of postoperative morbidity, and a 1 to 6 percent risk of perioperative mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?19/29/19930/abstract/27-29\">",
"     27-29",
"    </a>",
"    ]. Postoperative complications typically delay (or even preclude) chemotherapy.",
"   </p>",
"   <p>",
"    Another argument against surgery is the relatively low risk of bleeding (3 percent) or",
"    <span class=\"nowrap\">",
"     obstruction/perforation",
"    </span>",
"    (7 to 14 percent) in patients who present with stage IV disease and an intact asymptomatic primary who are managed at least initially without resection [",
"    <a class=\"abstract\" href=\"UTD.htm?19/29/19930/abstract/27,30-33\">",
"     27,30-33",
"    </a>",
"    ]. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one large series, only 16 of 233 patients (7 percent) initially unresected patients required emergency surgery for obstruction or perforation [",
"      <a class=\"abstract\" href=\"UTD.htm?19/29/19930/abstract/30\">",
"       30",
"      </a>",
"      ]. For those who did require emergency surgery, the perioperative mortality rate was relatively high (13 percent).",
"     </li>",
"     <li>",
"      Additional data are available from a phase II trial of the National Surgical Adjuvant Breast and Bowel Project (NSABP C-10 trial) in which all enrolled patients were treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/32/33280?source=see_link\">",
"       fluorouracil",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/54/24423?source=see_link\">",
"       leucovorin",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/11/2233?source=see_link\">",
"       oxaliplatin",
"      </a>",
"      (mFOLFOX6) in combination with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/20/2377?source=see_link\">",
"       bevacizumab",
"      </a>",
"      without resection of the primary tumor [",
"      <a class=\"abstract\" href=\"UTD.htm?19/29/19930/abstract/34\">",
"       34",
"      </a>",
"      ]. The primary objective of the study was to determine the rate of major morbidity, while the secondary objectives included survival, chemotherapy-related toxicity, and determination of the specific events related to the primary tumor that require hospitalization or major intervention, but not surgery. In this study, the majority of patients with metastatic disease and an asymptomatic primary tumor could be safely spared an initial resection. At a median follow up of 20.7 months, the cumulative incidence of major morbidity was 16.3 percent and only 10 of the 86 enrolled patients (12 percent) required surgery (eight for obstruction, one for perforation, and one for pain). There were two patient deaths (one from obstruction and one from perforation) and four secondary events, of which three were obstruction and one was percutaneous drainage of an abscess. Survival did not appear to be compromised by leaving the primary tumor intact (median overall survival 19.9 months).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There are no guidelines for identifying patients with unresected CRC who are likely to suffer complications and require surgery during systemic therapy. The risk of future obstruction may be lower with right as compared to left sided tumors. However, others have shown that even patients who appear to be at high risk for subsequent complications because of tumor site or colonoscopic findings (ie, a nearly obstructing lesion or inability to advance the scope beyond the tumor) can be well controlled with modern chemotherapy, obviating the need for palliative surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?19/29/19930/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Largely because of these issues, and the high rates of morbidity with primary tumor resection in patients with unresectable distant metastases (12 and 21 percent for major and minor morbidity, respectively, in one report [",
"    <a class=\"abstract\" href=\"UTD.htm?19/29/19930/abstract/31\">",
"     31",
"    </a>",
"    ]), guidelines from the",
"    <a class=\"external\" href=\"file://www.nccn.org/professionals/physician_gls/f_guidelines.asp\">",
"     National Comprehensive Cancer Network",
"    </a>",
"    suggest that bowel resection be considered in asymptomatic individuals with unresectable metastatic disease only if there is an imminent risk of obstruction or significant bleeding.",
"   </p>",
"   <p>",
"    The philosophy of deferring primary site resection in asymptomatic patients with incurable metastatic disease has been called into question by several analyses suggesting that resection of the primary may slow progression and favorably impact survival [",
"    <a class=\"abstract\" href=\"UTD.htm?19/29/19930/abstract/36,37\">",
"     36,37",
"    </a>",
"    ], although this is not a universal finding [",
"    <a class=\"abstract\" href=\"UTD.htm?19/29/19930/abstract/27,38-40\">",
"     27,38-40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a SEER database study of 26,754 patients presenting with stage IV CRC between 1988 and 2000, 17,658 (66 percent) underwent surgical resection of the primary tumor [",
"      <a class=\"abstract\" href=\"UTD.htm?19/29/19930/abstract/36\">",
"       36",
"      </a>",
"      ]. Surgical resection was more often undertaken in younger patients and in those with colonic as opposed to rectal tumors. Among patients presenting with metastatic disease (but not peritoneal carcinomatosis), those who underwent resection had a higher median (11 versus 2 months) and one-year survival rate (46 versus 11 percent) compared to those who did not. However, there was no information as to case selection, symptoms, chemotherapy treatment, or burden of metastatic disease. A major problem with upfront surgery is that if the patient suffers a long-lasting complication (eg, wound infection, anastomotic leak), systemic chemotherapy would be delayed.",
"     </li>",
"     <li>",
"      Perhaps the most compelling evidence supporting a survival benefit for resection of the primary site comes from a retrospective pooled analysis of individual data from 810 patients with synchronous unresectable metastatic disease who were enrolled in four prospective randomized trials of first line chemotherapy for stage IV colorectal cancer, 478 of whom had primary site resection and 332 did not [",
"      <a class=\"abstract\" href=\"UTD.htm?19/29/19930/abstract/37\">",
"       37",
"      </a>",
"      ]. In a preliminary report presented at the 2012 annual meeting of the American Society of Clinical Oncology (ASCO), resection of the primary tumor was independently associated with improved survival. After adjustment for differences in primary site location, and serum levels of the tumor marker carcinoembryonic antigen (CEA) and alkaline phosphatase, the hazard ratio [HR] for death in resected patients was 0.63, 95% CI 0.53-0.75. There was a significant interaction between resection and CEA levels as well as primary site. The greatest survival impact from resection of the primary site was seen in patients with a rectal primary who had low CEA levels (0 to 20",
"      <span class=\"nowrap\">",
"       ng/mL),",
"      </span>",
"      while there was no benefit in those with a colonic primary and very high CEA levels (&gt;600",
"      <span class=\"nowrap\">",
"       ng/mL).",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The reason why patients with metastatic disease might have a survival benefit from resection of the primary tumor is unclear, although a similar relationship between resection of the primary site and improved outcomes has been shown in metastatic renal cell cancer and metastatic breast cancer. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/6/22630?source=see_link\">",
"     \"Role of surgery in patients with metastatic renal cell carcinoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/12/4292?source=see_link\">",
"     \"Role of breast surgery for stage IV breast cancer\"",
"    </a>",
"    .).",
"   </p>",
"   <p>",
"    Importantly, none of the above series reporting a survival benefit for resection of the primary site have assessed the contribution of systemic chemotherapy to outcomes, or controlled for all possible variables that could have favorably affected outcomes in the resected patients. In fact, a Cochrane review of seven non-randomized studies, totaling 1086 patients, concluded that resection of the primary cancer in asymptomatic patients with unresectable stage IV CRC who were managed with",
"    <span class=\"nowrap\">",
"     chemo/radiotherapy",
"    </span>",
"    was",
"    <strong>",
"     not",
"    </strong>",
"    associated with a consistent improvement in overall survival and did not significantly reduce the risk of primary site complications (obstruction, perforation, bleeding) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/29/19930/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition, a survival benefit for resection of the primary in patients with unresectable liver metastases was noted in the randomized FFCD 9601 trial, which evaluated different first-line chemotherapy regimens in patients with metastatic CRC [",
"    <a class=\"abstract\" href=\"UTD.htm?19/29/19930/abstract/41\">",
"     41",
"    </a>",
"    ]. Among the 216 patients presenting with synchronous metastases, 156 had undergone resection of their primary site prior to study enrollment. Median overall survival was significantly longer in those who had primary site resection (16.3 versus 9.8 months, p &lt;0.0001), and in multivariate analysis, resection of the primary was the strongest independent prognostic factor for both progression-free and overall survival.",
"   </p>",
"   <p>",
"    In our view, these data provide support for randomized trials of primary site resection in patients who present with unresectable metastatic disease, two of which are currently ongoing (the Dutch",
"    <a class=\"external\" href=\"file://www.clinicaltrials.gov/ct2/show/NCT01606098?term=CAIRO4&amp;rank=1\">",
"     CAIRO4",
"    </a>",
"    and German SYNCHRONOUS trials [",
"    <a class=\"abstract\" href=\"UTD.htm?19/29/19930/abstract/42\">",
"     42",
"    </a>",
"    ]), but should not yet change the standard of care in these patients. Until further information becomes available, we agree with the current guidelines from the",
"    <a class=\"external\" href=\"file://www.nccn.org/professionals/physician_gls/f_guidelines.asp\">",
"     National Comprehensive Cancer Network",
"    </a>",
"    and do not advocate primary site resection in patients with an asymptomatic primary site who have unresectable metastatic disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Methods for surgical palliation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The methods for surgical palliation for patients with symptomatic colon or rectal cancer with incurable metastatic disease include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Resection of cancer and primary anastomosis",
"     </li>",
"     <li>",
"      Diverting end colostomy with mucous fistula",
"     </li>",
"     <li>",
"      Bypass procedure",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For patients who can tolerate an intra-abdominal procedure, the optimal palliative procedure is a resection with a primary anastomosis. However, resection or primary anastomosis may not be possible in all clinical settings because of extensive local disease involving adjacent structures, or serious comorbid illnesses. In these situations, a diverting end colostomy with creation of a mucous fistula is the procedure of choice, especially in patients with distal colonic tumors. The mucous fistula decompresses the secretions from the distally obstructed segment of bowel. An end colostomy rather than a loop colostomy is preferred because it is easier to manage with fewer complications. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/12/28873?source=see_link&amp;anchor=H21063116#H21063116\">",
"     \"Surgical principles of ostomy construction\", section on 'Incidence of stomal complications'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For patients with unresectable obstructing cancers, a bypass between the small bowel and the colon distal to the obstruction can be performed. However, if the patient has a competent ileocecal valve, there is potential for distention of the bypassed segment and eventual closed loop obstruction due to the accumulation of secretions in the bypassed colon. In these cases, the cecum can be tacked to the abdominal wall with seromuscular sutures, and surgical clips can be placed in the abdominal wall to mark the area where a potential percutaneous drain can be placed at a later time if necessary.",
"   </p>",
"   <p>",
"    Regardless of the method of surgical palliation, the laparoscopic approach to colorectal resection is preferred to minimize the risk of postoperative complications. While there are no data from randomized trials or prospective studies regarding the optimal approach (open versus laparoscopic) for surgical palliation, we believe the data from trials of colectomy for colon resection for colorectal cancer in the nonpalliative setting are directly applicable. Randomized trials in that setting have shown equivalent cancer outcomes and lower morbidity with the laparoscopic approach. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/16/34057?source=see_link&amp;anchor=H87591486#H87591486\">",
"     \"Surgical oncologic principles for resection of primary rectal adenocarcinoma\", section on 'Laparoscopic versus open approach'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Additionally, the data from a retrospective review in the palliative setting are consistent with the general technical outcomes for laparoscopic colectomies. In 904 patients with stage IV colorectal cancer, patients undergoing laparoscopic resection (n=226) had significantly fewer postoperative complications when compared with those undergoing open resection (17 versus 24 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/29/19930/abstract/43\">",
"     43",
"    </a>",
"    ]. Patients undergoing laparoscopic resection also had a shorter length of stay (14 versus 17 days), but a similar median survival (25.9 versus 22.3 months). However, there was a 12 percent conversion rate from a laparoscopic to an open approach due to unanticipated tumor bulk or invasion into adjacent structures.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Nonsurgical palliative options",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Intraluminal stent placement",
"    </span>",
"    &nbsp;&mdash;&nbsp;Successful local palliation of an obstructing or nearly obstructing tumor may be achieved through endoscopic or radiographic placement of self-expanding metal stent (SEMS). Among the advantages of SEMS over palliative surgery are a faster recovery time (permitting earlier administration of chemotherapy) and a shorter hospital stay [",
"    <a class=\"abstract\" href=\"UTD.htm?19/29/19930/abstract/44-46\">",
"     44-46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Potential complications include perforation and stent migration. As an example, in a retrospective series of 37 patients undergoing placement of a SEMS for an obstructing rectosigmoid cancer, three had early stent dislodgement [",
"    <a class=\"abstract\" href=\"UTD.htm?19/29/19930/abstract/47\">",
"     47",
"    </a>",
"    ]. At a median follow-up 7 months, 27 (78 percent) had successful restoration of luminal patency and resolution of obstructive symptoms; two patients required a second stent placement because of tumor growth either at the distal or proximal end, two had delayed perforations, and one had a late distal migration. Tumor ingrowth has only occasionally been reported; when it occurs, it can be successfully treated with laser ablation and the insertion of overlapping stents. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/34/5673?source=see_link\">",
"     \"Enteral stents for the management of malignant colorectal obstruction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Accumulating data suggest a significantly increased risk of perforation in patients treated with the antiangiogenic agent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    . Thus, colonic stenting should not be performed in patients who are receiving bevacizumab. These data are addressed in detail elsewhere [",
"    <a class=\"abstract\" href=\"UTD.htm?19/29/19930/abstract/48\">",
"     48",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/54/43882?source=see_link&amp;anchor=H1651227458#H1651227458\">",
"     \"Toxicity of molecularly targeted antiangiogenic agents: Non-cardiovascular effects\", section on 'Bevacizumab'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/34/5673?source=see_link&amp;anchor=H9#H9\">",
"     \"Enteral stents for the management of malignant colorectal obstruction\", section on 'Perforation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Local tumor ablation",
"    </span>",
"    &nbsp;&mdash;&nbsp;If the tumor is not completely obstructing, electrofulguration or laser ablation (using a NdYAG or argon ion [argon plasma coagulation or APC] laser) can be attempted to maintain the patency of the lumen [",
"    <a class=\"abstract\" href=\"UTD.htm?19/29/19930/abstract/49-56\">",
"     49-56",
"    </a>",
"    ]. Laser ablation is effective in restoring luminal patency in 88 to 97 percent of patients with obstructive symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?19/29/19930/abstract/54-56\">",
"     54-56",
"    </a>",
"    ]. However, most patients require more than one treatment session, and the risk of perforation is significant, especially with repeated applications. Furthermore, the duration of palliation may be short.",
"   </p>",
"   <p>",
"    Electrofulguration",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    laser ablation can also be attempted in patients with rectal bleeding. Radiation therapy directed at the primary tumor may is another alternative to control bleeding.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6297599\">",
"    <span class=\"h2\">",
"     Rectal cancer and pelvic radiotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are established treatment paradigms for rectal cancer in patients without metastatic disease. Total mesorectal excision improves rates of local control and recurrence-free survival compared to other surgical options. For patients with T3 or node-positive disease, the addition adjuvant radiation therapy (RT) and adjuvant chemotherapy improves outcomes over radical surgery alone. The combination of preoperative chemotherapy and RT in patients with locally advanced disease is association with fewer local recurrences and improved sphincter preservation rates, although a survival benefit compared to postoperative chemoradiotherapy has not been shown. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/16/34057?source=see_link&amp;anchor=H87590296#H87590296\">",
"     \"Surgical oncologic principles for resection of primary rectal adenocarcinoma\", section on 'Total mesorectal excision'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/51/4922?source=see_link&amp;anchor=H23407468#H23407468\">",
"     \"Adjuvant therapy for resected rectal cancer\", section on 'Meta-analysis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/22/42346?source=see_link&amp;anchor=H11#H11\">",
"     \"Neoadjuvant chemoradiotherapy and radiotherapy for rectal cancer\", section on 'Neoadjuvant chemoradiotherapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are no established guidelines for treatment of the rectal primary in patients with resectable, synchronous liver metastases, and in particular, the role of pelvic RT. However, the available data support the view that in such patients, the predominant pattern of disease recurrence is distant, not local and that the addition of pelvic RT does not significantly reduce rates of local recurrence or improve disease-specific survival. Thus, while RT has a clear role in improving rates of sphincter preservation for low-lying tumors, and in patients for whom the likelihood of achieving a complete (R0) resection is in doubt based upon local disease extent, the omission of RT may be reasonable in patients without these issues who have a simultaneous diagnosis of resectable liver metastases This subject is addressed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/22/42346?source=see_link&amp;anchor=H6299256#H6299256\">",
"     \"Neoadjuvant chemoradiotherapy and radiotherapy for rectal cancer\", section on 'Elimination of pelvic RT in patients with synchronous liver metastases'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients who present with synchronous metastatic disease and a symptomatic primary tumor (obstruction, bleeding, perforation), resection of the primary tumor is warranted. Even patients with incurable metastatic disease can benefit from surgical palliation for symptoms of obstruction and bleeding from the primary tumor.",
"   </p>",
"   <p>",
"    For patients who are not candidates for resection, proximal diversion, or nonsurgical methods of palliation (endoluminal placement of a self-expanding metal stent, or laser ablation for nonobstructing tumors) can be attempted.",
"   </p>",
"   <p>",
"    For patients who are asymptomatic and who have potentially resectable metastatic disease, resection of the primary is also indicated as part of an aggressive management strategy aimed at cure. For patients with asymptomatic primary tumors and unresectable metastatic disease, the decision whether or not to resect the primary must be individualized and based upon an estimate of the risks versus benefits of surgery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     AGGRESSIVE CYTOREDUCTION AND INTRAPERITONEAL CHEMOTHERAPY FOR PERITONEAL CARCINOMATOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to lymphatic and hematogenous spread, colon cancers may give rise to transcoelomic spread within the peritoneal cavity, resulting in peritoneal carcinomatosis. Until recently, most oncologists viewed peritoneal carcinomatosis as a terminal condition, to be palliated only with systemic chemotherapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/32/44554?source=see_link\">",
"     \"Systemic chemotherapy for metastatic colorectal cancer: Completed clinical trials\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, in approximately 25 percent of cases, the peritoneal cavity is the only site of metastatic disease after a detailed workup of the lungs and liver. This has led some to hypothesize that in some cases, peritoneal carcinomatosis may represent a first site of dissemination, and therefore, not necessarily indicative of generalized disease [",
"    <a class=\"abstract\" href=\"UTD.htm?19/29/19930/abstract/57-59\">",
"     57-59",
"    </a>",
"    ]. This appears to be rare overall. In a combined series of 2095 patients with metastatic CRC who were enrolled in two chemotherapy trials, 364 (17 percent) had peritoneal carcinomatosis, but only 44 (2.1 percent) had peritoneal carcinomatosis as the sole presentation of metastatic disease [",
"    <a class=\"abstract\" href=\"UTD.htm?19/29/19930/abstract/60\">",
"     60",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    A similar paradigm is hypothesized for appendiceal cancer, which also has a propensity to spread intraperitoneally. Radical surgical cytoreduction and intraperitoneal (IP) chemotherapy has gained acceptance for the treatment of diffuse peritoneal adenomucinosis (pseudomyxoma peritonei) and selected patients with peritoneal dissemination of an appendiceal adenocarcinoma (mucinous peritoneal carcinomatosis). This approach is also applied to malignant peritoneal mesothelioma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/14/36074?source=see_link\">",
"     \"Cancer of the appendix and pseudomyxoma peritonei\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/21/17754?source=see_link\">",
"     \"Malignant peritoneal mesothelioma: Epidemiology, risk factors, clinical presentation, diagnosis, and staging\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For patients with isolated peritoneal carcinomatosis from colorectal cancer, benefit for cytoreductive surgery with heated intraperitoneal chemotherapy has been suggested in several retrospective case series, a multi-institutional registry review [",
"    <a class=\"abstract\" href=\"UTD.htm?19/29/19930/abstract/61\">",
"     61",
"    </a>",
"    ], two randomized trials, and a systematic review.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H340772390\">",
"    <span class=\"h2\">",
"     Randomized trials",
"    </span>",
"    &nbsp;&mdash;&nbsp;To date, two randomized controlled trials have been conducted of surgical cytoreduction followed by heated (hyperthermic) intraperitoneal chemotherapy (HIPEC) for patients with peritoneal dissemination of CRC; neither used modern combination chemotherapy as the control arm [",
"    <a class=\"abstract\" href=\"UTD.htm?19/29/19930/abstract/62,63\">",
"     62,63",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the first trial, 105 patients with established peritoneal carcinomatosis of colorectal (n = 87) or appendiceal (n = 18) origin were randomly assigned to cytoreductive surgery and HIPEC with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/16/38144?source=see_link\">",
"     mitomycin",
"    </a>",
"    C followed by systemic chemotherapy (5-FU and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/54/24423?source=see_link\">",
"     leucovorin",
"    </a>",
"    ), or systemic 5-FU and leucovorin alone with palliative surgery as needed [",
"    <a class=\"abstract\" href=\"UTD.htm?19/29/19930/abstract/62\">",
"     62",
"    </a>",
"    ]. Despite the high postoperative mortality rate (8 percent), the median disease-specific survival in the IP treatment group was significantly longer (22 versus 13 months). At a median follow-up of eight years, 45 percent of patients in the IP chemotherapy arm who underwent complete cytoreduction (no residual tumor nodules) were still alive [",
"    <a class=\"abstract\" href=\"UTD.htm?19/29/19930/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The use of a modern systemic",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    -containing regimen in the control arm could potentially have narrowed and even eliminated the survival difference between the groups, since median survival durations in contemporary reports approximate 20 months. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/32/44554?source=see_link\">",
"     \"Systemic chemotherapy for metastatic colorectal cancer: Completed clinical trials\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The second trial, which also randomly assigned patients to aggressive surgical cytoreduction with hyperthermic IP chemotherapy or systemic therapy (5-FU-based), only accrued 35 of the planned cohort of 90 patients (30 CRC, 5 appendiceal cancers) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/29/19930/abstract/63\">",
"     63",
"    </a>",
"    ]. Although the two-year survival rate of patients undergoing cytoreduction and IP chemotherapy was 60 percent (much higher than would be expected among patients treated with systemic",
"    <span class=\"nowrap\">",
"     5-FU/",
"     <a class=\"drug drug_general\" href=\"UTD.htm?23/54/24423?source=see_link\">",
"      leucovorin",
"     </a>",
"    </span>",
"    chemotherapy), the difference in survival between the experimental and control groups was not statistically significant.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Systematic review",
"    </span>",
"    &nbsp;&mdash;&nbsp;A systematic review of published data of cytoreductive surgery and IP chemotherapy for peritoneal dissemination of CRC, including the two randomized trials described above [",
"    <a class=\"abstract\" href=\"UTD.htm?19/29/19930/abstract/62,63\">",
"     62,63",
"    </a>",
"    ], one comparative study [",
"    <a class=\"abstract\" href=\"UTD.htm?19/29/19930/abstract/65\">",
"     65",
"    </a>",
"    ], a multi-institutional registry series (an earlier report than described above [",
"    <a class=\"abstract\" href=\"UTD.htm?19/29/19930/abstract/66\">",
"     66",
"    </a>",
"    ]), and several case series came to the following conclusions [",
"    <a class=\"abstract\" href=\"UTD.htm?19/29/19930/abstract/67\">",
"     67",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Median survival varied from 13 to 29 months, and five-year survival rates ranged from 11 to 19 percent.",
"     </li>",
"     <li>",
"      Patients who underwent complete surgical cytoreduction appeared to benefit the most, with median survival 28 to 60 months, and five-year survival from 22 to 49 percent.",
"     </li>",
"     <li>",
"      This survival benefit was achieved at a cost of overall treatment-related morbidity rates between 23 to 44 percent and mortality rates from 0 to 12 percent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although these results seem promising, many unanswered questions remain. The major issue is whether these results are better than could be achieved using modern",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    -based systemic chemotherapy with or without biologic agents. These regimens have greater activity as compared to 5-FU and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/54/24423?source=see_link\">",
"     leucovorin",
"    </a>",
"    alone. Median survival durations in unselected patients with metastatic disease are 22 to 24 months, and approximately 10 percent of patients remain alive at five years. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/32/44554?source=see_link\">",
"     \"Systemic chemotherapy for metastatic colorectal cancer: Completed clinical trials\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The only data that specifically address the efficacy of modern systemic chemotherapy in patients with isolated peritoneal carcinomatosis come from a retrospective analysis of 48 highly-selected patients with peritoneal carcinomatosis from CRC who were treated with an",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    -containing palliative chemotherapy regimen at one of five French comprehensive cancer centers (where cytoreductive surgery and HIPEC were not available) over a five-year period [",
"    <a class=\"abstract\" href=\"UTD.htm?19/29/19930/abstract/68\">",
"     68",
"    </a>",
"    ]. These patients were selected as the control group on the basis of their meeting clinicopathologic criteria defined as good prognostic factors for HIPEC [",
"    <a class=\"abstract\" href=\"UTD.htm?19/29/19930/abstract/63\">",
"     63",
"    </a>",
"    ]. The two-and five-year survival rates were 65 and 13 percent, respectively, and the median survival was 24 months.",
"   </p>",
"   <p>",
"    In contrast, the median, two- and five-year survival rates for a separate group of 48 patients who underwent cytoreductive surgery and HIPEC for CRC peritoneal carcinomatosis during the same time period at the Gustave Roussy Institute were 63 months, and 81 and 51 percent, respectively.",
"   </p>",
"   <p>",
"    The authors concluded that, in appropriately selected patients with isolated peritoneal carcinomatosis, results with cytoreductive surgery and HIPEC are superior to those that can be achieved with modern combination chemotherapy regimens. The retrospective nature of this analysis, and the inherent bias in comparing non-randomly assigned patients limits the confidence with which this conclusion can be judged.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;While patients who undergo complete cytoreduction followed by HIPEC seem to have a more favorable prognosis than can be achieved with systemic chemotherapy alone, in our view, there remains insufficient evidence to conclude whether the survival advantage is due to treatment or to biologic features that allow these patients to undergo complete cytoreductive surgery. Furthermore, the quality of the cytoreductive surgery is dependent upon the skills and level of experience of the surgeon. The favorable results (particularly with regard to treatment-related toxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?19/29/19930/abstract/61,69\">",
"     61,69",
"    </a>",
"    ]) achieved by international experts in the field may not be replicated in routine clinical practice. Finally, the independent contribution of HIPEC to the success of this approach has not been proven. Randomized trials are needed.",
"   </p>",
"   <p>",
"    Based upon all of these issues, in our view (and that of the National Comprehensive Cancer Network [NCCN] [",
"    <a class=\"abstract\" href=\"UTD.htm?19/29/19930/abstract/70\">",
"     70",
"    </a>",
"    ]), this approach should not be considered standard at present and only pursued in centers with demonstrated expertise [",
"    <a class=\"abstract\" href=\"UTD.htm?19/29/19930/abstract/71\">",
"     71",
"    </a>",
"    ], preferably in the context of a clinical trial. Such a trial, USMCI",
"    <span class=\"nowrap\">",
"     8214/ACOSOG",
"    </span>",
"    Z6091 in which patients with peritoneal carcinomatosis from colorectal cancer were randomized to standard systemic chemotherapy or surgical cytoreduction with heated intraperitoneal chemotherapy followed by systemic chemotherapy was closed for lack of accrual. Another trial, Prodige 7, in which patients with isolated intraperitoneal metastases from CRC are randomly assigned to cytoreductive surgery with or without HIPEC, is underway in France. An international list of centers with expertise in treatment of peritoneal surface malignancies is available online [",
"    <a class=\"abstract\" href=\"UTD.htm?19/29/19930/abstract/72,73\">",
"     72,73",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?19/27/19890?source=see_link\">",
"       \"Patient information: Colon and rectal cancer (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?6/0/6148?source=see_link\">",
"       \"Patient information: Colon and rectal cancer (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?39/22/40293?source=see_link\">",
"       \"Patient information: Colorectal cancer treatment; metastatic cancer (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgery provides a potentially curative option for selected patients who present with limited metastatic colorectal cancer (CRC). If the metastases are potentially resectable, especially if they are located in one organ system (such as liver or lung), both the primary and the metastases should be managed aggressively. With integration of surgery and chemotherapy, long-term survival can be achieved in as many as 50 percent of cases. For patients with borderline resectable metastatic disease, downstaging with neoadjuvant chemotherapy may permit later successful resection. Even patients who are not candidates for a curative resection can benefit from surgical palliation for symptoms of obstruction and bleeding from the primary tumor. These patients must be managed by a multidisciplinary team. (See",
"    <a class=\"local\" href=\"#H1\">",
"     'Introduction'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Management of the primary tumor",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with a symptomatic primary tumor (bleeding, obstruction, perforation) and synchronous potentially resectable stage IV disease who are candidates for surgery, we suggest upfront resection of the primary tumor followed by chemotherapy and reevaluation for metastasectomy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Symptomatic primary'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients who are candidates for surgical palliation, we suggest using the laparoscopic approach when feasible (",
"      <a class=\"grade\" href=\"._grade_4?title=Grade 2A\">",
"       Grade 2A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Methods for surgical palliation'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/23/16762?source=see_link&amp;anchor=H125359914#H125359914\">",
"       \"Surgical oncologic principles for the resection of colon cancer\", section on 'Laparoscopic colectomy'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/16/34057?source=see_link&amp;anchor=H87591486#H87591486\">",
"       \"Surgical oncologic principles for resection of primary rectal adenocarcinoma\", section on 'Laparoscopic versus open approach'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For symptomatic patients who are not candidates for resection, other options for management of the primary tumor include surgical bypass, diverting colostomy and mucous fistula or loop colostomy, placement of an intraluminal self-expanding metal stent, or for nonobstructing tumors, laser ablation. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Methods for surgical palliation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients who present with stage IV disease who are not symptomatic from the primary tumor, an aggressive approach is warranted if the metastases are potentially resectable for cure. We suggest initial systemic chemotherapy to allow the natural history of disease progression to become manifest, followed by reevaluation and resection of both the primary tumor and metastases in the absence of widespread disease progression (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Asymptomatic'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with incurable metastatic disease who are receiving chemotherapy, the decision whether or not to resect an asymptomatic primary tumor must be individualized, with careful consideration of the risk to benefit ratio. Preliminary results from NSABP C-10 suggest that the majority can be spared initial surgery without compromising survival, although questions remain as to whether there is a survival benefit to upfront surgery. Until additional data are available, we suggest not pursuing initial resection of the primary tumor in the absence of symptoms (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Incurable metastatic disease'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Potentially resectable hepatic, lung, ovarian, retroperitoneal lymph nodes, and adrenal metastases",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Recommendations for surgical management of potentially resectable hepatic metastases (including a discussion as to integration of systemic chemotherapy into the surgical paradigm) and resection of pulmonary metastases are discussed in detail elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/55/41850?source=see_link\">",
"       \"Management of potentially resectable colorectal cancer liver metastases\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/15/13560?source=see_link\">",
"       \"Surgical resection of pulmonary metastases: Outcomes by histology\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/32/13834?source=see_link\">",
"       \"Surgical resection of pulmonary metastases: Benefits; indications; preoperative evaluation and techniques\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients with metastatic disease involving retroperitoneal lymph nodes attempted resection is reasonable if the primary is controlled and the staging evaluation shows no evidence of disease at other sites, although recurrence rates are high. (See",
"      <a class=\"local\" href=\"#H12027710\">",
"       'Retroperitoneal nodes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For the rare patient with a single adrenal metastasis, resection is a reasonable option if the primary is controlled and the staging evaluation shows no evidence of extra adrenal disease involvement; however, this decision must be individualized. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Isolated adrenal metastases'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Resection is also reasonable for patients with symptomatic bulky ovarian metastases, even in the presence of extraovarian metastatic disease. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Ovarian metastases'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Peritoneal carcinomatosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Optimal management of patients with peritoneal carcinomatosis without distant disease after a rigorous diagnostic work-up is controversial. Although accumulating data suggests that long-term survival can be achieved in a small number of patients using aggressive surgical cytoreduction followed by hyperthermic intraperitoneal chemotherapy, the major unanswered issue is whether these results are better than could be achieved using modern",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    -based systemic chemotherapy with or without biologic agents. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/32/44554?source=see_link\">",
"     \"Systemic chemotherapy for metastatic colorectal cancer: Completed clinical trials\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In our view (and that of the National Comprehensive Cancer Network [NCCN] [",
"    <a class=\"abstract\" href=\"UTD.htm?19/29/19930/abstract/70\">",
"     70",
"    </a>",
"    ]), this approach should not be considered standard at present, and only pursued in centers with demonstrated expertise, preferably in the context of a clinical trial. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Aggressive cytoreduction and intraperitoneal chemotherapy for peritoneal carcinomatosis'",
"    </a>",
"    above.)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Surveillance, Epidemiology and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Incidence - SEER 17 Regs Limited-Use, Nov 2006 Sub (1973-2004 varying), National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2007, based on the November 2006 submission.",
"    </li>",
"    <li>",
"     AJCC (American Joint Committee on Cancer) Cancer Staging Manual, 7th edition, Edge, SB, Byrd, DR, Compton, CC, et al (Eds) (Eds), Springer, New York 2010. p.143.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/29/19930/abstract/3\">",
"      Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013; 63:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/29/19930/abstract/4\">",
"      Shah SA, Haddad R, Al-Sukhni W, et al. Surgical resection of hepatic and pulmonary metastases from colorectal carcinoma. J Am Coll Surg 2006; 202:468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/29/19930/abstract/5\">",
"      Cedermark BJ, Blumenson LE, Pickren JW, et al. Ths significance of metastases to the adrenal glands in adenocarcinoma of the colon and rectum. Surg Gynecol Obstet 1977; 144:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/29/19930/abstract/6\">",
"      Mourra N, Hoeffel C, Duvillard P, et al. Adrenalectomy for clinically isolated metastasis from colorectal carcinoma: report of eight cases. Dis Colon Rectum 2008; 51:1846.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/29/19930/abstract/7\">",
"      Fujita K, Kameyama S, Kawamura M. Surgically removed adrenal metastasis from cancer of the rectum. Report of a case. Dis Colon Rectum 1988; 31:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/29/19930/abstract/8\">",
"      Katayama A, Mafune K, Makuuchi M. Adrenalectomy for solitary adrenal metastasis from colorectal carcinoma. Jpn J Clin Oncol 2000; 30:414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/29/19930/abstract/9\">",
"      Watatani M, Ooshima M, Wada T, et al. Adrenal metastasis from carcinoma of the colon and rectum: a report of three cases. Surg Today 1993; 23:444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/29/19930/abstract/10\">",
"      Kanjo T, Albertini M, Weber S. Long-term disease-free survival after adrenalectomy for isolated colorectal metastases. Asian J Surg 2006; 29:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/29/19930/abstract/11\">",
"      Marangos IP, Kazaryan AM, Rosseland AR, et al. Should we use laparoscopic adrenalectomy for metastases? Scandinavian multicenter study. J Surg Oncol 2009; 100:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/29/19930/abstract/12\">",
"      de Haas RJ, Rahy Martin AC, Wicherts DA, et al. Long-term outcome in patients with adrenal metastases following resection of colorectal liver metastases. Br J Surg 2009; 96:935.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/29/19930/abstract/13\">",
"      Segelman J, Fl&ouml;ter-R&aring;destad A, Hellborg H, et al. Epidemiology and prognosis of ovarian metastases in colorectal cancer. Br J Surg 2010; 97:1704.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/29/19930/abstract/14\">",
"      Kim DD, Park IJ, Kim HC, et al. Ovarian metastases from colorectal cancer: a clinicopathological analysis of 103 patients. Colorectal Dis 2009; 11:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/29/19930/abstract/15\">",
"      Fujiwara A, Noura S, Ohue M, et al. Significance of the resection of ovarian metastasis from colorectal cancers. J Surg Oncol 2010; 102:582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/29/19930/abstract/16\">",
"      Go&eacute;r&eacute; D, Daveau C, Elias D, et al. The differential response to chemotherapy of ovarian metastases from colorectal carcinoma. Eur J Surg Oncol 2008; 34:1335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/29/19930/abstract/17\">",
"      McCormick CC, Giuntoli RL 2nd, Gardner GJ, et al. The role of cytoreductive surgery for colon cancer metastatic to the ovary. Gynecol Oncol 2007; 105:791.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/29/19930/abstract/18\">",
"      Rayson D, Bouttell E, Whiston F, Stitt L. Outcome after ovarian/adnexal metastectomy in metastatic colorectal carcinoma. J Surg Oncol 2000; 75:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/29/19930/abstract/19\">",
"      Choi PW, Kim HC, Kim AY, et al. Extensive lymphadenectomy in colorectal cancer with isolated para-aortic lymph node metastasis below the level of renal vessels. J Surg Oncol 2010; 101:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/29/19930/abstract/20\">",
"      Min BS, Kim NK, Sohn SK, et al. Isolated paraaortic lymph-node recurrence after the curative resection of colorectal carcinoma. J Surg Oncol 2008; 97:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/29/19930/abstract/21\">",
"      Shibata D, Paty PB, Guillem JG, et al. Surgical management of isolated retroperitoneal recurrences of colorectal carcinoma. Dis Colon Rectum 2002; 45:795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/29/19930/abstract/22\">",
"      Biasco G, Derenzini E, Grazi G, et al. Treatment of hepatic metastases from colorectal cancer: many doubts, some certainties. Cancer Treat Rev 2006; 32:214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/29/19930/abstract/23\">",
"      Saltz LB. Metastatic colorectal cancer: is there one standard approach? Oncology (Williston Park) 2005; 19:1147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/29/19930/abstract/24\">",
"      Ho TW, Mack LA, Temple WJ. Operative salvage for retroperitoneal nodal recurrence in colorectal cancer: a systematic review. Ann Surg Oncol 2011; 18:697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/29/19930/abstract/25\">",
"      Gervaz P, Rubbia-Brandt L, Andres A, et al. Neoadjuvant chemotherapy in patients with stage IV colorectal cancer: a comparison of histological response in liver metastases, primary tumors, and regional lymph nodes. Ann Surg Oncol 2010; 17:2714.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/29/19930/abstract/26\">",
"      Brouquet A, Mortenson MM, Vauthey JN, et al. Surgical strategies for synchronous colorectal liver metastases in 156 consecutive patients: classic, combined or reverse strategy? J Am Coll Surg 2010; 210:934.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/29/19930/abstract/27\">",
"      Scoggins CR, Meszoely IM, Blanke CD, et al. Nonoperative management of primary colorectal cancer in patients with stage IV disease. Ann Surg Oncol 1999; 6:651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/29/19930/abstract/28\">",
"      Ruo L, Gougoutas C, Paty PB, et al. Elective bowel resection for incurable stage IV colorectal cancer: prognostic variables for asymptomatic patients. J Am Coll Surg 2003; 196:722.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/29/19930/abstract/29\">",
"      Galizia G, Lieto E, Orditura M, et al. First-line chemotherapy vs bowel tumor resection plus chemotherapy for patients with unresectable synchronous colorectal hepatic metastases. Arch Surg 2008; 143:352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/29/19930/abstract/30\">",
"      Poultsides GA, Servais EL, Saltz LB, et al. Outcome of primary tumor in patients with synchronous stage IV colorectal cancer receiving combination chemotherapy without surgery as initial treatment. J Clin Oncol 2009; 27:3379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/29/19930/abstract/31\">",
"      Scheer MG, Sloots CE, van der Wilt GJ, Ruers TJ. Management of patients with asymptomatic colorectal cancer and synchronous irresectable metastases. Ann Oncol 2008; 19:1829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/29/19930/abstract/32\">",
"      Nitzkorski JR, Farma JM, Watson JC, et al. Outcome and natural history of patients with stage IV colorectal cancer receiving chemotherapy without primary tumor resection. Ann Surg Oncol 2012; 19:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/29/19930/abstract/33\">",
"      Cirocchi R, Trastulli S, Abraha I, et al. Non-resection versus resection for an asymptomatic primary tumour in patients with unresectable stage IV colorectal cancer. Cochrane Database Syst Rev 2012; 8:CD008997.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/29/19930/abstract/34\">",
"      McCahill LE, Yothers G, Sharif S, et al. Primary mFOLFOX6 plus bevacizumab without resection of the primary tumor for patients presenting with surgically unresectable metastatic colon cancer and an intact asymptomatic colon cancer: definitive analysis of NSABP trial C-10. J Clin Oncol 2012; 30:3223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/29/19930/abstract/35\">",
"      Ballian N, Mahvi DM, Kennedy GD. Colonoscopic findings and tumor site do not predict bowel obstruction during medical treatment of stage IV colorectal cancer. Oncologist 2009; 14:580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/29/19930/abstract/36\">",
"      Cook AD, Single R, McCahill LE. Surgical resection of primary tumors in patients who present with stage IV colorectal cancer: an analysis of surveillance, epidemiology, and end results data, 1988 to 2000. Ann Surg Oncol 2005; 12:637.",
"     </a>",
"    </li>",
"    <li>",
"     Faron M,Bourredjem A, Pignon JP, et al. Impact on survival of primary tumor resection in patients with colorectal cancer and unresectable metastasis: pooled analysis of individual patients' data from four randomized trials. J Clin Oncol 30, 2012 (suppl; abstr 3507). Abstract available online at file://www.asco.org/ASCOv2/Meetings/Abstracts?&amp;vmview=abst_detail_view&amp;confID=114&amp;abstractID=98587 (Accessed on June 19, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/29/19930/abstract/38\">",
"      Tebbutt NC, Norman AR, Cunningham D, et al. Intestinal complications after chemotherapy for patients with unresected primary colorectal cancer and synchronous metastases. Gut 2003; 52:568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/29/19930/abstract/39\">",
"      Stelzner S, Hellmich G, Koch R, Ludwig K. Factors predicting survival in stage IV colorectal carcinoma patients after palliative treatment: a multivariate analysis. J Surg Oncol 2005; 89:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/29/19930/abstract/40\">",
"      Karoui M, Koubaa W, Delbaldo C, et al. Chemotherapy has also an effect on primary tumor in colon carcinoma. Ann Surg Oncol 2008; 15:3440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/29/19930/abstract/41\">",
"      Ferrand F, Malka D, Bourredjem A, et al. Impact of primary tumour resection on survival of patients with colorectal cancer and synchronous metastases treated by chemotherapy: results from the multicenter, randomised trial F&eacute;d&eacute;ration Francophone de Canc&eacute;rologie Digestive 9601. Eur J Cancer 2013; 49:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/29/19930/abstract/42\">",
"      Rahbari NN, Lordick F, Fink C, et al. Resection of the primary tumour versus no resection prior to systemic therapy in patients with colon cancer and synchronous unresectable metastases (UICC stage IV): SYNCHRONOUS--a randomised controlled multicentre trial (ISRCTN30964555). BMC Cancer 2012; 12:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/29/19930/abstract/43\">",
"      Hida K, Hasegawa S, Kinjo Y, et al. Open versus laparoscopic resection of primary tumor for incurable stage IV colorectal cancer: a large multicenter consecutive patients cohort study. Ann Surg 2012; 255:929.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/29/19930/abstract/44\">",
"      Tilney HS, Lovegrove RE, Purkayastha S, et al. Comparison of colonic stenting and open surgery for malignant large bowel obstruction. Surg Endosc 2007; 21:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/29/19930/abstract/45\">",
"      Karoui M, Charachon A, Delbaldo C, et al. Stents for palliation of obstructive metastatic colon cancer: impact on management and chemotherapy administration. Arch Surg 2007; 142:619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/29/19930/abstract/46\">",
"      Vemulapalli R, Lara LF, Sreenarasimhaiah J, et al. A comparison of palliative stenting or emergent surgery for obstructing incurable colon cancer. Dig Dis Sci 2010; 55:1732.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/29/19930/abstract/47\">",
"      Spinelli P, Mancini A. Use of self-expanding metal stents for palliation of rectosigmoid cancer. Gastrointest Endosc 2001; 53:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/29/19930/abstract/48\">",
"      Cennamo V, Fuccio L, Mutri V, et al. Does stent placement for advanced colon cancer increase the risk of perforation during bevacizumab-based therapy? Clin Gastroenterol Hepatol 2009; 7:1174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/29/19930/abstract/49\">",
"      Kimmey MB. Endoscopic methods (other than stents) for palliation of rectal carcinoma. J Gastrointest Surg 2004; 8:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/29/19930/abstract/50\">",
"      Loizou LA, Grigg D, Boulos PB, Bown SG. Endoscopic Nd:YAG laser treatment of rectosigmoid cancer. Gut 1990; 31:812.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/29/19930/abstract/51\">",
"      Daneker GW Jr, Carlson GW, Hohn DC, et al. Endoscopic laser recanalization is effective for prevention and treatment of obstruction in sigmoid and rectal cancer. Arch Surg 1991; 126:1348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/29/19930/abstract/52\">",
"      Mesko TW, Petrelli NJ, Rodriguez-Bigas M, Nava H. Endoscopic laser treatment for palliation of colorectal adenocarcinoma. Surg Oncol 1993; 2:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/29/19930/abstract/53\">",
"      Tan CC, Iftikhar SY, Allan A, Freeman JG. Local effects of colorectal cancer are well palliated by endoscopic laser therapy. Eur J Surg Oncol 1995; 21:648.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/29/19930/abstract/54\">",
"      Spinelli P, Mancini A, Dal Fante M. Endoscopic treatment of gastrointestinal tumors: indications and results of laser photocoagulation and photodynamic therapy. Semin Surg Oncol 1995; 11:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/29/19930/abstract/55\">",
"      Mathus-Vliegen EM, Tytgat GN. Analysis of failures and complications of neodymium: YAG laser photocoagulation in gastrointestinal tract tumors. A retrospective survey of 18 years' experience. Endoscopy 1990; 22:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/29/19930/abstract/56\">",
"      Farouk R, Ratnaval CD, Monson JR, Lee PW. Staged delivery of Nd:YAG laser therapy for palliation of advanced rectal carcinoma. Dis Colon Rectum 1997; 40:156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/29/19930/abstract/57\">",
"      Jayne DG, Fook S, Loi C, Seow-Choen F. Peritoneal carcinomatosis from colorectal cancer. Br J Surg 2002; 89:1545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/29/19930/abstract/58\">",
"      Sugarbaker PH. Management of peritoneal-surface malignancy: the surgeon's role. Langenbecks Arch Surg 1999; 384:576.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/29/19930/abstract/59\">",
"      Glehen O, Osinsky D, Beaujard AC, Gilly FN. Natural history of peritoneal carcinomatosis from nongynecologic malignancies. Surg Oncol Clin N Am 2003; 12:729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/29/19930/abstract/60\">",
"      Franko J, Shi Q, Goldman CD, et al. Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841. J Clin Oncol 2012; 30:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/29/19930/abstract/61\">",
"      Elias D, Gilly F, Boutitie F, et al. Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study. J Clin Oncol 2010; 28:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/29/19930/abstract/62\">",
"      Verwaal VJ, van Ruth S, de Bree E, et al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol 2003; 21:3737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/29/19930/abstract/63\">",
"      Elias D, Delperro JR, Sideris L, et al. Treatment of peritoneal carcinomatosis from colorectal cancer: impact of complete cytoreductive surgery and difficulties in conducting randomized trials. Ann Surg Oncol 2004; 11:518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/29/19930/abstract/64\">",
"      Verwaal VJ, Bruin S, Boot H, et al. 8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer. Ann Surg Oncol 2008; 15:2426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/29/19930/abstract/65\">",
"      Mahteme H, Hansson J, Berglund A, et al. Improved survival in patients with peritoneal metastases from colorectal cancer: a preliminary study. Br J Cancer 2004; 90:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/29/19930/abstract/66\">",
"      Glehen O, Kwiatkowski F, Sugarbaker PH, et al. Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study. J Clin Oncol 2004; 22:3284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/29/19930/abstract/67\">",
"      Yan TD, Black D, Savady R, Sugarbaker PH. Systematic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis from colorectal carcinoma. J Clin Oncol 2006; 24:4011.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/29/19930/abstract/68\">",
"      Elias D, Lefevre JH, Chevalier J, et al. Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin. J Clin Oncol 2009; 27:681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/29/19930/abstract/69\">",
"      Yan TD, Zappa L, Edwards G, et al. Perioperative outcomes of cytoreductive surgery and perioperative intraperitoneal chemotherapy for non-appendiceal peritoneal carcinomatosis from a prospective database. J Surg Oncol 2007; 96:102.",
"     </a>",
"    </li>",
"    <li>",
"     National Comprehensive Cancer Network (NCCN) guidelines. Available at: www.nccn.org (Accessed on May 15, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/29/19930/abstract/71\">",
"      Esquivel J, Sticca R, Sugarbaker P, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of peritoneal surface malignancies of colonic origin: a consensus statement. Society of Surgical Oncology. Ann Surg Oncol 2007; 14:128.",
"     </a>",
"    </li>",
"    <li>",
"     www.surgicaloncology.com/txsites.htm (Accessed on June 30, 2011).",
"    </li>",
"    <li>",
"     file://www.pmppals.org/surgeons-and-specialists.html (Accessed on April 20, 2011).",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2495 Version 22.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-199.231.185.123-BC6E475435-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_29_19930=[""].join("\n");
var outline_f19_29_19930=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H20\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12027618\">",
"      OUTCOMES AFTER RESECTION OF ISOLATED METASTATIC DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      Limited hepatic and pulmonary metastatic disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Isolated adrenal metastases",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Ovarian metastases",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12027710\">",
"      Retroperitoneal nodes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      MANAGEMENT OF THE PRIMARY CANCER IN PATIENTS PRESENTING WITH SYNCHRONOUS METASTASES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6297413\">",
"      Surgical issues",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Symptomatic primary",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Asymptomatic",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Potentially curable metastatic disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Incurable metastatic disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Methods for surgical palliation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Nonsurgical palliative options",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Intraluminal stent placement",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Local tumor ablation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6297599\">",
"      Rectal cancer and pelvic radiotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Summary",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      AGGRESSIVE CYTOREDUCTION AND INTRAPERITONEAL CHEMOTHERAPY FOR PERITONEAL CARCINOMATOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H340772390\">",
"      Randomized trials",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Systematic review",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Summary",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Management of the primary tumor",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Potentially resectable hepatic, lung, ovarian, retroperitoneal lymph nodes, and adrenal metastases",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Peritoneal carcinomatosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/2495\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/2495|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/26/23982\" title=\"table 1\">",
"      2010 TNM staging colorectal CA",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/51/4922?source=related_link\">",
"      Adjuvant therapy for resected rectal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/14/36074?source=related_link\">",
"      Cancer of the appendix and pseudomyxoma peritonei",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/34/5673?source=related_link\">",
"      Enteral stents for the management of malignant colorectal obstruction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/21/17754?source=related_link\">",
"      Malignant peritoneal mesothelioma: Epidemiology, risk factors, clinical presentation, diagnosis, and staging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/55/41850?source=related_link\">",
"      Management of potentially resectable colorectal cancer liver metastases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/22/42346?source=related_link\">",
"      Neoadjuvant chemoradiotherapy and radiotherapy for rectal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?6/0/6148?source=related_link\">",
"      Patient information: Colon and rectal cancer (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?19/27/19890?source=related_link\">",
"      Patient information: Colon and rectal cancer (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?39/22/40293?source=related_link\">",
"      Patient information: Colorectal cancer treatment; metastatic cancer (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/12/4292?source=related_link\">",
"      Role of breast surgery for stage IV breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/6/22630?source=related_link\">",
"      Role of surgery in patients with metastatic renal cell carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/16/34057?source=related_link\">",
"      Surgical oncologic principles for resection of primary rectal adenocarcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/23/16762?source=related_link\">",
"      Surgical oncologic principles for the resection of colon cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/12/28873?source=related_link\">",
"      Surgical principles of ostomy construction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/32/13834?source=related_link\">",
"      Surgical resection of pulmonary metastases: Benefits; indications; preoperative evaluation and techniques",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/15/13560?source=related_link\">",
"      Surgical resection of pulmonary metastases: Outcomes by histology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/32/44554?source=related_link\">",
"      Systemic chemotherapy for metastatic colorectal cancer: Completed clinical trials",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/20/21833?source=related_link\">",
"      Systemic chemotherapy for metastatic colorectal cancer: General principles",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/54/43882?source=related_link\">",
"      Toxicity of molecularly targeted antiangiogenic agents: Non-cardiovascular effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/37/11866?source=related_link\">",
"      Treatment of locally advanced unresectable or recurrent rectal cancer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_29_19931="DSM-IV-TR diagnostic criteria for cannabis intoxication";
var content_f19_29_19931=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PSYCH%2F73321&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PSYCH%2F73321&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    DSM-IV-TR diagnostic criteria for cannabis intoxication",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       The four criteria for cannabis intoxication are:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       1. Recent use of cannabis.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       2. Clinically significant maladaptive behavioral or psychological changes, such as euphoria, anxiety, sensation of slowed time, impaired motor coordination, or social withdrawal. These changes develop during or shortly after cannabis use.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       3. Two or more of the following physiologic symptoms within two hours of cannabis use:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       a. Conjunctival injection",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       b. Increased appetite",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       c. Dry mouth",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       d. Tachycardia",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       4. The symptoms are not due to a general nonpsychiatric medical condition and are not better accounted for by another mental disorder.",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reprinted with permission from: the Diagnostic and Statistical Manual of Mental Disorders, Text Revision, Fourth Edition (Copyright 2000). American Psychiatric Association.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_29_19931=[""].join("\n");
var outline_f19_29_19931=null;
var title_f19_29_19932="Interventional therapy in aortic dissection";
var content_f19_29_19932=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F75376&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F75376&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    European Society of Cardiology guidelines: Interventional therapy in aortic dissection",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Recommendation",
"       </td>",
"       <td class=\"subtitle1_single\">",
"        Class",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1. Stenting of obstructed branch origin for static obstruction of branch artery",
"       </td>",
"       <td>",
"        IIa",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2. Balloon fenestration of dissecting membrane plus stenting of aortic true lumen for dynamic obstruction",
"       </td>",
"       <td>",
"        IIa",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3. Stenting to keep fenestration open",
"       </td>",
"       <td>",
"        IIa",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4. Fenestration to provide re-entry tear for dead-end false lumen",
"       </td>",
"       <td>",
"        IIa",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"2\">",
"        5. Stenting of true lumen",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        to seal entry (covered stent)",
"       </td>",
"       <td class=\"sublist_other\">",
"        IIb",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        enlarge compressed true lumen",
"       </td>",
"       <td class=\"sublist_other\">",
"        IIa",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"2\" rowspan=\"1\">",
"        Classification",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\" rowspan=\"1\">",
"        <strong>",
"         Class I:",
"        </strong>",
"        Conditions for which there is evidence and/or general agreement that a given procedure or treatment is useful and effective.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"2\" rowspan=\"1\">",
"        <strong>",
"         Class II:",
"        </strong>",
"        Conditions for which there is conflicting evidence and/or a divergence of opinion about the usefulness/efficacy of a procedure or treatment.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\" colspan=\"2\" rowspan=\"1\">",
"        <strong>",
"         Class IIa:",
"        </strong>",
"        Weight of evidence/opinion is in favor of usefulness/efficacy.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\" colspan=\"2\" rowspan=\"1\">",
"        <strong>",
"         Class IIb:",
"        </strong>",
"        Usefulness/efficacy less well established by evidence/opinion.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\" rowspan=\"1\">",
"        <strong>",
"         Class III:",
"        </strong>",
"        Conditions for which there is evidence and/or general agreement that the procedure/treatment is not useful and in some cases may be harmful.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data reproduced with permission from Erbel, R, Alfonso, F, Boileau, C, et al, Eur Heart J 2001; 22:1642.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_29_19932=[""].join("\n");
var outline_f19_29_19932=null;
var title_f19_29_19933="Evaluation and management of suspected encephalitis in children";
var content_f19_29_19933=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F51779&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F51779&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Initial evaluation and management of suspected encephalitis in children older than one month of age",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        History",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Symptoms: fever; depressed or altered level of consciousness; lethargy; personality change; emotional lability; seizure; ataxia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Travel",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Exposure (animals, insects, freshwater swimming, toxins)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Immunizations",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Immune status",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Physical findings",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vital signs and general examination",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Neurologic examination, particularly for focal findings and GCS",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Laboratory studies",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Screening laboratories: CBC; glucose; electrolytes; BUN; creatinine; ammonia; blood pH; blood cultures; LFTs; urinalysis; urine drug screen; save a sample of acute serum",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lumbar puncture: perform emergently, often after neuroimaging if a focal lesion is suspected; obtain opening pressure when clinically feasible; send CSF for cell count/differential, glucose, protein, bacterial culture, HSV PCR, enterovirus PCR; save a sample of CSF",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Other laboratory tests to consider: influenza testing during influenza season; tests for toxic metabolic encephalopathy and inborn errors of metabolism (see text); antibody studies for NMDAR and VGKC (see text)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Ancillary studies",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Neuroimaging: MRI preferred, but CT if MRI not promptly available, impractical, or cannot be performed",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        EEG:&nbsp;as soon as is feasible&nbsp;(for evidence of encephalitis or nonconvulsive seizure)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Treatment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Stabilization",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Support airway, breathing and circulation:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Endotracheal intubation for GCS &le;8 or compromised airway",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Fluid resuscitation with normal saline (20 mL/kg, initial bolus) for signs of shock",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Obtain rapid glucose; treat if hypoglycemic with 2.5 mL/kg of 10 percent dextrose solution",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Treat seizures with lorazepam (0.1 mg/kg intravenously) or equivalent benzodiazepine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Empiric therapy (initial dose)*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Treat for influenza, as indicated, during influenza season with oseltamivir (0 to 3 months: 12 mg orally; 4 to 5 months: 17 mg orally; 6 to 11 months: 24 mg orally; &ge;12 months and &le;15 kg: 30 mg orally; 15 to 23 kg: 45 mg orally; 23 to 40 kg: 60 mg orally; &gt;40 kg and/or &gt;12 years old: 75 mg orally)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Administer acyclovir",
"        <sup>",
"         &bull;",
"        </sup>",
"        (&gt;29 days to &lt;12 years: 20 mg/kg intravenously; &ge;12 years: 10 mg/kg intravenously) to all patients without a specific diagnosis other than HSV",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Treat for bacterial meningitis as indicated (eg, vancomycin [15 mg/kg intravenously]",
"        <strong>",
"         plus either",
"        </strong>",
"        ceftriaxone [50 mg/kg intravenously]",
"        <strong>",
"         or",
"        </strong>",
"        cefotaxime [100 mg/kg intravenously])",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Treat for rickettsial infection (eg, Rocky Mountain spotted fever, Q fever) or ehrlichiosis in children at risk (doxycycline [2.2 mg/kg intravenously or orally])",
"        <sup>",
"         &loz;",
"        </sup>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     GCS: Glasgow coma scale; CBC: complete blood count; BUN: blood urea nitrogen; LFT: liver function tests; CSF: cerebrospinal fluid; HSV: herpes simplex virus; PCR: polymerase chain reaction; NMDAR: anti-N-methyl-D-aspartate receptor; VGKC: voltage-gated potassium channel; MRI: magnetic resonance imaging; CT: computed tomography; EEG: electroencephalography.",
"     <br>",
"      * The medication doses listed in the section on \"Empiric therapy\" are",
"      <strong>",
"       initial",
"      </strong>",
"      doses. Please refer to the text for information about ongoing dosing and care.",
"      <br>",
"       <font class=\"bullet\">",
"        &bull;",
"       </font>",
"       Presumptive treatment for herpes simplex virus.",
"       <br>",
"        &Delta; For patients in whom bacterial meningitis cannot be excluded.",
"        <br>",
"         <font class=\"lozenge\">",
"          &loz;",
"         </font>",
"         Exposure to ticks in endemic regions; exposure to cats, sheep, goats; blood smear characteristic of ehrlichiosis.",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_29_19933=[""].join("\n");
var outline_f19_29_19933=null;
var title_f19_29_19934="Pancoast tumor PET";
var content_f19_29_19934=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F81147&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F81147&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pancoast tumor",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 229px; height: 444px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    PET image showing intense metabolic activity in the apical mass but no adenopathy.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_29_19934=[""].join("\n");
var outline_f19_29_19934=null;
var title_f19_29_19935="Papulonecrotic tuberculid on extremities";
var content_f19_29_19935=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F74606&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F74606&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Papulonecrotic tuberculid",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 256px; height: 372px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A symmetrical eruption of erythematous to violaceous papules is present on the legs of this patient with papulonecrotic tuberculid.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Dr. M Ramam, New Delhi.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_29_19935=[""].join("\n");
var outline_f19_29_19935=null;
